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ABSTRACT 
 
Emilie R. Mainz : Direct Evaluation of Akt Kinase Activity with Single Cell Resolution: 
Innovations in the Development of Peptide Reporters for Use with Capillary Electrophoresis 
(Under the direction of Nancy L. Allbritton) 
 
Direct quantification of kinase activity at the single cell level has long been a goal 
from both a drug development and diagnostic standpoint. This is true for measurements of 
the protein kinase Akt, which is known to drive aberrant cell growth and metabolism in 
diseases including rheumatoid arthritis and pancreatic cancer. A more complete mechanistic 
profile of abnormal Akt activity in these diseases could drive the development of targeted 
inhibitors or companion diagnostics, but is hindered by the small and heterogeneous samples 
that can often be obtained from patients. Established tools including genetically encoded 
sensors and high throughput mass cytometry are incompatible with these primary samples. 
 Herein, a novel chemical cytometry approach is presented which utilizes peptide-
based reporters to deliver direct measurements of Akt activity in single cells from cell lines 
as well as clinical samples. Methodological and chemical innovations resulted in the 
development of rapid and low cost assay development strategies, use of non-native amino 
acids as methods to impart additional stability on peptide probes, analysis of individual cells 
from rheumatoid arthritis subjects, and significant improvement in the overall throughput of 
analysis.  
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Chapter 1: The Akt Pathway: Disease Implications and Assay Strategies 
 
1.1 Protein Kinases and The Akt Pathway 
1.1.1 Protein Kinases: Key Regulators of Cellular Functions 
Physiology is greatly influenced by a diverse group of intracellular enzymes which 
catalyze the chemical reactions required for typical cellular functions. Of these reactions, 
post-translational modifications (PTMs) are an important device by which the functional 
diversity of proteins is expanded while maintaining tight regulatory control.1,2 For example, 
ubiquitin is often conjugated to proteins fated for degradation by the ubiquitin-proteasome 
pathway.3 This PTM-based selection of specific proteins ensures that the proteolytic process 
is highly discerning, which is critical for preventing excessive breakdown of cellular 
contents. Such PTMs modulate the activity of most eukaryotic proteins, and include 
phosphorylation, proteolysis, acetylation, dephosphorylation, glycosylation and methylation.1 
Among the best studied are protein kinases, which catalyze phosphorylation; the addition of a 
phosphoryl group (PO3
2-) from a high energy adenosine triphosphate (ATP) molecule to a 
serine, threonine, or tyrosine residue on a protein substrate.4 The electrostatic properties of 
the substrate are modified by the dual negative charges imparted by phosphorylation, which 
in turn alters the structure, function, or localization of the protein substrate.5 Protein kinases 
play critical roles in cell growth, metabolism, and survival; activating these pathways through 
rapid exchange of phosphoryl groups allows normal cells to swiftly react to stimuli and 
afterwards return to basal enzyme activity.6 Therefore, diseases which rely heavily on 
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atypical cell growth or metabolism can often be traced to one or more dysregulated kinase 
pathways. Aberrations of protein kinases in cancer are likely the most well-known example.7 
1.1.2 A Brief History of Protein Kinases and Inhibitors 
 Prior to 1950, phosphorylated proteins were known to exist but were considered 
biologically inert.8 The characterization of phosphorylase kinase by Fisher and Krebs in 1955 
founded the field of protein kinases and later earned them a Nobel Prize.6,9 By the late 1980s, 
major roles of protein kinases in disease had been established through the discovery of 
receptor tyrosine kinases (RTKs) and others as oncogenes.10,11 Advancements in medicinal 
chemistry then yielded the discovery of the natural product staurosporine, a potent kinase 
inhibitor which also proved spectacularly nonspecific, and thus highly toxic.12-14  
 In 2001, the first blockbuster protein kinase inhibitor, imatinib, was developed. Often 
hailed as the paragon of targeted cancer therapy, imatinib inhibits the constitutively active 
driving force in chronic myelogenous leukemia (CML): the BCR/ABL fusion protein.7 A 
landmark study by O’Brien and colleagues demonstrated therapeutic effect in 87% of 
patients versus 34% with standard treatment, effectively converting CML from fatal disease 
to manageable condition.7,15 The efficacy of imatinib also popularized oncogene addiction, 
the concept that some cancers are reliant on a single prevailing mutation, as a route to 
targeted anti-cancer therapeutics. Bolstered by the fact that 19 kinase inhibitors gained FDA 
approval from 2011 through June 2015,16 pharmaceutical development pipelines are stocked 
with kinase inhibitors to treat a multitude of disorders, not limited to arthritis,17 solid 
tumors,18 and pulmonary fibrosis.19-21 Combination therapies with monoclonal antibodies or 
other small molecule inhibitors are also being explored for synergistic effects.22 Though 
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challenges in specificity and drug resistance remain, the impact of kinase inhibitors on 
modern medicine is undeniable. 
1.1.3 Akt Kinase 
The kinase Akt (Akt, also known as Protein Kinase B (PKB)) is a serine/threonine 
protein kinase recognized as a critical effector of survival-related cellular functions, 
including growth, proliferation, metabolism, and angiogenesis.23-26 Akt is a member of the 
AGC protein kinase family, which originally contained cAMP-dependent kinase (PKA), 
cGMP-dependent kinase (PKG), and protein kinase C (PKC), so grouped due to their 
conserved catalytic domains and similar regulatory features.27 The three isoforms of Akt 
(1/α, 2/ß, and 3/γ) are products of distinct genes but perform similar functions and possess 
80% sequence homology.28 Akt possesses an N-terminal pleckstrin homology (PH) domain 
that allows for recruitment to the membrane, a central kinase catalytic domain, and a short C-
terminal regulatory domain that governs the interaction between signaling molecules.26  
Since Akt elicits a broad spectrum of cell growth and survival behaviors, its 
activation is a tightly regulated process involving recruitment to the membrane and dual 
phosphorylation.29 When upstream pathways including RTKs, cytokine receptors, integrins, 
or specific G-protein coupled receptors (GPCRs) are stimulated, phosphoinositide 3-kinase 
(PI3K) activation is triggered.30 PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate 
(PIP2) to generate phosphatidylinositol (3,4,5)-triphosphate (PIP3),which acts as a ligand to 
the PH domain of Akt, anchoring it to the plasma membrane (Figure 1.1) . Partial activation 
of Akt is achieved by the phosphorylation of threonine 308 in the kinase domain by 
phosphoinositide dependent kinase -1 (PDK-1). This level of Akt activity is sufficient to 
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catalyze some downstream protein synthesis activities.31 The enzyme or enzymes responsible 
for full activation of Akt by phosphorylation at serine 473 was the subject of much debate. 
Several studies in the 2000s confirmed that target of rapamycin complex 2 (TORC2), DNA-
activated protein kinase (DNA-PK) and potentially rapamycin-insensitive TORC1 have this 
capability.32-35 Once fully activated by dual phosphorylation, Akt diffuses away from the 
membrane to the cytosol or nucleus to phosphorylate downstream targets. When returning to 
basal signaling, Akt activity is reduced indirectly by the actions of phosphatase and tensin 
homolog (PTEN), which dephosphorylates PIP3 to PIP2 and acting to sever the PH domain 
interactions mooring Akt to the membrane.36 Activity can also be halted by direct 
dephosphorylation at Thr308 or Ser473 by protein phosphatase 2A (PP2A) and PH-domain 
leucine-rich repeat protein kinase 1or 2 (PHLPP1/2), respectively. Though regulated tightly, 
aberrations at any of these signaling nodes can manifest in disease. Of the 538 kinases 
currently identified, those involved in the PI3K/Akt/mTOR pathway are often cited as the 
most frequently dysregulated in cancer and other diseases. 37 This dissertation will focus 
primarily on the distinct roles of Akt in pancreatic ductal adenocarcinoma (PDAC) and 
rheumatoid arthritis (RA).  
1.2 Roles of Akt in Select Diseases 
1.2.1 Pancreatic Ductal Adenocarcinoma  
 PDAC is the fourth leading cause of cancer-related death and is almost universally 
fatal, with five year survival rates of 7%.38 PDAC is characterized by early and rapid 
metastasis with resistance to conventional and targeted therapeutic agents.39 The role of 
deviant Akt signaling in PDAC is well established, either alone or as a result of upstream 
oncogenic KRAS activity.29,40-44 It is reported that up to 70% of these tumors have a critical 
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dependency on hyperactive Akt for tumorigenesis45, since Akt contributes to cancer 
hallmarks such as unregulated cell growth and survival.29,46 These results are consistent with 
the correlation between elevated Akt activity and higher mortality rate in PDAC.47,48 
Aberrant Akt signaling in PDAC usually arises by one of three mechanisms. The rarest is 
direct mutation of the PH domain of Akt at position 49 (G to A), allowing it to associate with 
the membrane without the need for PI3K activation, resulting in a constitutively active 
kinase.49,50 Akt gene amplification, mRNA and protein overexpression has also been 
reported.51 Most frequently, deletion of the PTEN gene results in the loss of the primary 
negative feedback mechanism for Akt, increasing the overall activity.52 Recent work 
demonstrates that inhibition of PI3K with small molecules such as wortmannin and 
LY294002 sensitizes PDAC to pro-apoptotic stimuli and cytotoxic agents, making this 
signaling arm attractive for the development of targeted therapies.37,53,54 Mounting evidence 
also suggests that rare populations of rapidly growing and aggressively invasive cells are 
often responsible for tumor metastasis or recurrence, but can be targeted through Akt 
inhibition.55-57 Single cell analyses would be essential to the identification of these rare cell 
groups that would favorably respond to Akt inhibition even when the bulk of the tumor does 
not show overactivation of this pathway, thereby guiding appropriate prescription of anti-Akt 
therapies.  
1.2.2 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is the most common autoimmune disorder, and affects 
more than 1.3 million Americans.58 Despite innovations in engineered biologic therapies, the 
management of RA remains challenging and its success varies across patients. This 
variability in clinical management highlights the fact that RA is not a distinct disease entity, 
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but rather a complex syndrome with varied manifestations.59 The exact etiology of RA 
remains uncertain, but is known to involve synovial hyperplasia leading to cartilage 
destruction and irreversible joint damage.60 A mounting body of evidence suggests that 
Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS) contribute largely to this process by 
the infiltration and destruction of cartilage.61-63 Early RA is typically only observed in a 
limited number of joints before spreading throughout the body; this progression has been 
linked to the transmigration of activated FLS.64,65 It is postulated that selective destruction or 
growth inhibition of these cells which irreparably damage joints would be an excellent 
therapy, but thus far the signal transduction pathway aberrances leading to this invasive 
phenotype are largely unknown.  
While in the past it may have been assumed a priori that the signaling pathways 
involved in RA maintain too much plasticity to address with targeted kinase inhibitor 
therapies, recent successes with inhibitors such as tofacitinib and baricitinib, both of which 
inhibit the Jak/Stat pathway, have added to growing evidence that numerous protein kinases 
are dysregulated in RA, and many autoimmune disorders in general.17,66,67 Akt is a common 
downstream element of the majority of promiscuous chemokine signaling pathways that may 
be targeted for the next generation of anti-inflammatory drugs. Patients with RA have been 
found to possess Akt expression and activity abnormalities.68,69 Akt is implicated in an anti-
apoptotic role, allowing survival of cells responsible for synovial inflammation and eventual 
cartilage erosion.70 These abnormalities are seen primarily in rheumatoid arthritis FLS and 
not in neighboring macrophages or other cell types, suggesting that overactive Akt in these 
cells may incite aggressive anti-apoptotic and invasive behavior, progressing the disease. 
7 
 
 In addition to therapies consisting of Akt inhibitors, there is significant interest in 
utilizing Akt activity as a biomarker of patients who may be responsive to therapies targeting 
tumor necrosis factor alpha (TNFα). Biologic anti-TNFα therapies dominate RA treatment, 
but more than a third of patients are unresponsive.71,72 Little is known regarding the 
mechanism of Akt activation by TNFα,73 but results indicate that Akt acts as a survival signal 
in RA FLS after being stimulated by TNFα. 68,74 Thus, patients with elevated Akt activity 
may respond to therapies which remove the TNFα stimulus. However, the presence of 
contaminating cell types other than FLS that do not possess elevated Akt activity, but are 
often analyzed as such in bulk cell analysis, make this aberrant signaling difficult to 
interrogate. Chapter 2 will detail the first assay capable of directly measuring Akt activity in 
single cells from FLS from patients with RA.  
1.3 Challenges in The Measurement of Akt Activity in Clinical Samples 
In order to fully grasp Akt involvement in disease and potential as a therapeutic 
target, enzyme activity measurements will need to be performed with single cell resolution. 
Traditionally, thousands or millions of cells are required to prepare bulk lysates for ensemble 
measurements of Akt activity. This practice returns an ensemble average of the entire 
population, and obscures valuable information that can contribute to better understanding of 
the molecular mechanisms of disease. Information is lost due to the astounding heterogeneity 
among populations of cells, even those which are genetically identical and residue in the 
same tissue or tumor.75 The following section will discuss the role of heterogeneity in protein 
kinase signaling and the benefits of single cell analysis for measuring Akt activity in clinical 
samples.  
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1.3.1 Heterogeneity in Kinase Signaling 
In stark contrast to long-held opinions of homogeneity, recent biological and 
technical developments have shown that isogenic populations of cells frequently possess 
variable morphology, epigenetic state, proliferation rates, and protein expression.76-78 These 
differences can be driven by selection pressure,79 pre-programmed mechanisms such as 
differentiation,80 or have stochastic causes.81-83 For protein kinase signaling, differences often 
arise due to assorted splicings of a single RNA transcript,84 leaky negative feedback 
systems,85 and the evolution of cells that develop different functional properties, such as 
those observed in PDAC and RA.74,77 All of these can contribute to a broad spectrum of 
kinase activity within a population of cells, which requires single cell analysis for accurate 
characterization. For example, utilizing techniques which can resolve kinase activity in single 
cells would easily disseminate a bimodal signaling distribution, while a bulk method would 
return a mean value that poorly reflects both groups.75,86 Similarly, a rare population (<1%) 
of cells from a population would likely go undetected with bulk methods.  
Interestingly, heterogeneity in Akt signaling is as much of a hallmark in healthy cells 
as those afflicted with disease.87 Since the Akt pathway is so frequently dysregulated in 
disease, it is hypothesized that heterogeneous activation of this pathway benefits healthy cells 
by preventing overactivation of the pathway in the whole population, which could lead to 
unfettered growth or even senescence. There is also evidence to suggest that regulatory 
mechanisms in healthy cells such as rapid dephosphorylation by PTEN are crucial to keeping 
Akt at bay. However, when these growth signals cannot be regulated and Akt remains active, 
disease (and heterogeneity) abounds. Analysis of many solid tumors and FLS have 
demonstrated that Akt aberrances allowing for oncogenic or aggressive growth behaviors 
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often only represent a sub-fraction of the entire population.87,88 It will be important to 
generate methodologies which can tease apart differences in the catalytic activity of Akt in 
healthy and diseased tissues. Since it has been shown that overexpressed Akt may not indeed 
be active, quantification of substrates and well as products of the kinase will be essential.89  
1.3.2 Analysis of Small or Complex Clinical Samples 
Basic research and the development of kinase inhibitors are reliant on immortalized 
cell lines, which are simple to culture, cost-effective, and produce rapid results. However, 
after several passages, cell characteristics can change and may become quite different to 
those found in the initial tissue. Increased growth rate, altered morphology, and 
modifications of cell surface marker expression have all been reported.90,91 This is all the 
more troubling when attempting to model complex and heterogeneous diseases such as 
PDAC and RA, which are not well-represented by a single isogenic cell type. For this reason, 
primary human tissues should be utilized when possible. The challenges with such clinical 
samples from both diseases of interest of this dissertation will be discussed.  
PDAC demonstrates marked genetic and phenotypic intratumoral heterogeneity that 
is thought to underlie the differential responses to standard chemotherapy. Research 
regarding Akt’s role in treatment resistance identifies the kinase as an arbiter of cancer stem 
cell (CSC) fate, allowing rare CSC cells to evade systemic cytotoxic therapies and 
recapitulate the tumor.55,57 Interestingly, rare subpopulations such as CSCs have been shown 
to be more sensitive than non-stem cells to Akt inhibition.56 These cells are linked to clinical 
observations where chemotherapy greatly shrinks the tumor but fails to eradicate it, 
indicating a rare resistant cell phenotype. However, rare subpopulations are difficult to 
10 
 
detect in the heterogeneous intratumoral environment characteristic to PDAC and may go 
entirely undetected by bulk sample analyses. The impact of Akt role in CSCs is further 
hampered by the inability of diagnostic tests to directly measure enzyme activity.  
  Rheumatoid Arthritis is a highly complex disease with many cell types playing major 
roles in inflammation. The study of FLS biology is difficult due to the heterogeneous cellular 
nature of the RA-affected synovium, which contains at least five mixed cell types. 
Additionally, the individual heterogeneity between FLS phenotypes, as well as the unique 
enzymology and biological processes within each individual patient, make quantification of 
Akt activity difficult in bulk cell analyses. Furthermore, new techniques including fine needle 
biopsies92 and ultrasound-guided sampling of synovial fluid93 are generally less invasive than 
a full synovectomy but produce very small numbers of cells, which are difficult to analyze 
with traditional techniques requiring thousands to millions of cells. The development of new 
technologies capable of probing FLS functional phenotypes and addressing individual FLS 
heterogeneity would greatly enhance the ability to characterize and ultimately develop new 
therapeutics which targets these cells.  
1.4 Assays for Measuring Akt Activity in Vitro, in Lysates or Single Cells 
Numerous methods have been utilized to detect either the presence of protein kinases 
or their associated activities. In this dissertation, a method for determination of kinase 
activity is defined as one capable of quantifying the rate of phosphorylated product formation 
(dP) or consumption of the substrate (dS), typically as a function of time (dP/dt= -dS/dt).94 In 
the following sections, customary methods as well as currently evolving single cell methods 
to detect Akt activity will be described.  
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1.4.1 In Vitro Assay Platforms 
1.4.1.1 Radioactive Assay Platforms 
Traditional radiometric assays exploit the fact that kinases require ATP as a 
phosphate source. By utilizing [γ-32P]-labeled ATP during the reaction, the transfer of 
radioactive 32P onto a protein substrate results in a radiolabeled protein or peptide substrate. 
After capturing the labeled substrate on a filter and washing to remove excess 32P-ATP, the 
amount of product formed is quantified by ß-scintillation counting.95 Morrow et al. utilized 
this method to compare the activity of Akt in response to upstream PI3K mutations in vitro 
and in lysates from a panel of colorectal cancer cell lines.96 However, the filter capture steps 
in this method have important practical drawbacks. Typically, phosphoric acid is utilized to 
impart a positive charge on the labeled substrate for adequate binding to the negatively 
charged phosphocellulose filter membranes, severely limiting the utility of negatively 
charged substrates, such as those employed in some Akt inhibitor screens.97,98  
The solution to the aforementioned issue is the homogenous scintillation proximity 
assay (SPA), which utilizes biotinylated peptide substrates.99 The 32P-tagged biotinylated 
peptide product is captured by SPA beads coated with streptavidin, bringing the scintillant in 
close proximity with the high energy radiolabel.100 SPA assays have shown to be comparable 
in accuracy to modern high throughput mass spectrometry-based assays of Akt activity.101 
Although SPA improves the throughput and accuracy of radiometric protein kinase assays, 
radioactive assay platforms in general have decreased in popularity because these assays 
generate prohibitively large amounts of waste that are both hazardous and expensive to 
dispose of for the end user.  
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1.4.1.2 Fluorescence–Based Technologies  
In many ways, in vitro fluorescence assays have become a favored alternative to in 
vitro radiometric assays to detect protein kinase activity. This is particularly true for high-
throughput applications. There are a wide variety of assays which are beyond the scope of 
this dissertation, but several key techniques will be summarized. A dominant fraction of 
these assays utilize homogeneous formats which do not require sample processing in terms of 
centrifugation, washing, or separation steps. They populate an impressive suite of 
applications, including fluorescence anisotropy, lifetime variation, quenching, Förster 
resonance energy transfer (FRET) and time correlation methods.  
1.4.1.2.1 Fluorescence Anisotropy 
Fluorescence anisotropy kinase assays rely on the differing rotational properties of 
large (>100,000 Da) and small (<10,000 Da) molecules to detect phosphorylated and native 
substrates.102 When molecules in solution are excited by plane polarized light, the degree to 
which the detected emission is polarized reflects the Brownian motion (i.e. rotations) the 
chromophore underwent between absorption and reemission. 103 Small molecules will tumble 
quickly and the resulting fluorescence is depolarized, or random, with respect to the 
polarization plane of the illuminating light. Conversely, small molecules which bind larger 
ones will experience a slower rotation or remain mostly stationary, and the detected emission 
will retain a comparable degree of polarization. Since the added phosphoryl group represents 
a very small mass change (80 Da),104 phosphorylation alone is not sufficient to differentiate 
native and phosphorylated substrates.  
Seethala was the first to describe an assay that utilized phospho-specific antibodies to 
selectively bind phosphorylated peptide substrates, imparting a mass sufficient for anisotropy 
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measurements.105 This technique remains popular with RTK detection, primarily because 
anti-phosphotyrosine antibodies are relatively insensitive to the amino acids surrounding the 
tyrosine, enabling use with a broad range of substrates.106 However, anti-
phosphothreonine/serine antibodies are considerably more sensitive to the surrounding 
context, and in some cases necessitating the development of a unique antibody for each 
substrate of interest.107 Numerous antibody-free solutions have been developed, including the 
use of cationic polyamino acids108 and mixtures of zinc sulfate and bovine serum albumin109 
to selectively add mass to negatively charged phosphopeptides. The Immobilized Metal Ion 
Affinity (IMAP, Molecular Devices, CA) assay utilizes cationic trivalent nanoparticles to 
complex with phosphopeptides generated during a kinase assay, and has met with success for 
detection of Akt activity in in vitro settings.100,110 The homogenous nature of these assays 
makes them favorable for automation in pharmaceutical lead development. Unfortunately, a 
classic downside of these assays is their susceptibility to interferences from complex samples 
or the substrates themselves, which can absorb light in the excitation or emission 
wavelengths of the assays, confounding anisotropy measurements. Turek-Etienne et al. 
overcame these limitations by developing red-shifted Cy3 and Cy5 labeled probes for Akt 
activity measurements in microbial extracts.111 Overall, fluorescence anisotropy 
measurements remain some of the simplest and most popular methods for high throughput 
screens of potential kinase inhibitors. However, the limited sensitivity and dynamic range of 
these assays precludes their use with highly complex samples or single cells.107  
1.4.1.2.2 Fluorescence Intensity Assays 
The emission characteristics of many fluorophores are directly influenced by their 
environment, including pH, solvent polarity, and nearby biological analytes. A classic 
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example is dansyl chloride, which has very low fluorescence in water until its reaction with 
primary amines.112 A similar strategy can be utilized to detect phosphorylation of peptides or 
proteins, where either an increase or decrease in fluorescence intensity signifies kinase 
activity. McIlroy et al. labeled a 25 amino acid PKC peptide with 6-acrylolyl-
dimethylaminonapthalene (acrylodan), which experiences a 20% loss in fluorescence upon 
phosphorylation. 113 By pairing the probe with an electrophoresis step, probe-derivatized 
phosphopeptide was separated from the unphosphorylated version, enabling ratiometric 
quantification of PKC activity in vitro and in crude brain lysates. In a quenching assay 
developed using similar trivalent cation chemistry to that applied in the IMAP assay,114 a 
phosphorylated peptide substrate is capable of quenching the fluorescence from a polymer 
deposited onto microspheres. Thus, a decrease in fluorescence correlates with kinase activity. 
These such methods are useful tools for the measurement of protein kinase activity in high 
throughput in vitro inhibitor screens and some lysates, but require large volumes (µL) which 
are not compatible with single cell analysis.  
1.4.1.2.3 Förster Resonance Energy Transfer Assays 
 FRET is a distance-dependent phenomenon in which a donor chromophore can non-
radiatively transfer energy to an acceptor molecule. Since FRET efficiency is principally 
dependent on the molecular propinquity of the donor and acceptor fluorophores (1-10 nm), it 
is often employed in biological studies that induce changes in conformation or proximity; 
these include protein kinase assays.  
FRET’s utility for in vitro kinase activity screens has been borne out in several 
commercial products. In the Z’-LYTE Kinase Assay (ThermoFisher Scientific, CA) a peptide 
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substrate with a centrally located protease clip site is adorned at each terminus with one 
member of a FRET fluorophore pair. Once the kinase reaction is complete, a proprietary 
cocktail containing a protease is added. If phosphorylated, the peptide substrate is immune to 
protease activity and remains intact. Conversely, any unmodified substrate will undergo 
cleavage at the central clip site, bringing the FRET pair into close proximity and increasing 
fluorescence. Thus, fluorescence intensifies when the kinase is inhibited. This assay is 
amenable to automation, and has been utilized by Pellechia and others to rapidly screen 
targeted Akt inhibitors, which verified the results of in silico methods to predict inhibitors 
based on known docking mechanisms.116 Though this assay is useful for detecting the 
efficacy of kinase inhibitors in vitro, its use with unmodified lysates should be approached 
with skepticism and requires careful triage. The presence of interfering intracellular proteases 
or peptidases may cleave the substrate even with the presence of a phosphoryl group, leading 
to a false positive (false inhibition) rate of up to 15%.117 Lysate studies are further 
complicated by the fact that substrates may not be optimized for specificity and thus 
phosphorylation may be due to several contributors.  
In an ambitious study to identify Akt inhibitors from a library of more than 63,000 
compounds, researchers at the UK Centre for Cancer Therapeutics utilized the 
AlphaScreen™ Technology (Perkin Elmer, Norwalk, CT); an antibody-based FRET assay.118 
This format utilizes a biotin-labeled Akt substrate, which is phosphorylated by Akt either 
from a recombinant source or from immunoprecipitated cell lysates. The addition of 
streptavidin-linked donor beads generates half of the FRET pair, which is completed when a 
phospho-specific antibody bound to protein-A labeled acceptor beads associates with the 
phosphorylated substrate. Therefore, fluorescence is only generated in the presence of 
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phosphorylated peptide, indicating the catalytic activity of Akt. With this method, the 
investigators identified that just 0.1% of the library compounds acted as significant Akt 
inhibitors. The primary limitation of this assay was the sensitivity of the donor beads to 
ambient light, which caused significant fluctuations in end-point fluorescence. False-
positives, generated through simple aggregation of the inhibitor and resulting in apparent 
enzyme inhibition, were found to be mitigated by testing apparent library hits in the presence 
of Triton X100, which reduces the aggregates.  
Overall, FRET-based in vitro fluorescence assays are useful to measure the potency 
of putative enzyme inhibitors, but require the kinase of interest of to exhibit high amounts of 
activity, which is not the case with several clinically important kinases.119 Another classic 
downside with these assays is the substrates or FRET pairs are often themselves fluorescent, 
resulting in high background.120 Furthermore, protein kinase inhibitor screens are often 
comprised of highly conjugated organic molecules which absorb light at wavelengths similar 
to those used for fluorescence emission. At typical compound screening concentrations of 
greater than 1 µM, interference artifacts can become significant. 
1.4.1.3 Mobility Shift Assays 
 Among the methods utilized to detect kinase activity in vitro, mobility shift assays 
comprise an outlier in a large group of homogenous assay formats. Rather than detect 
radioactive phosphorus or generate a fluorescent signal upon the gain or loss of kinase 
activity, these assays exploit the dissimilar net charge that phosphorylated proteins possess 
relative to native substrates.121 Caliper Technology (Caliper Life Sciences, Hopkinton, MA) 
is based on a microfluidic format which separates the product and substrate in an electric 
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field. This allows simultaneous detection of both, which can be monitored in real time.122 
However, when kinase activity in lysates is of interest, it is difficult to differentiate substrate 
phosphorylation from peptidase cleavage, since both may generate similar differences in 
electrophoretic mobility. Furthermore, these assays require large amounts of substrate (µM) 
and are low throughput. 
1.4.2 Assay Platforms for Single Cell Analysis 
In vitro studies or those utilizing lysates are a cost effective and simple model for 
investigating Akt activity, but they do not fully recapitulate the native cellular environment. 
Lysis disrupts local and encapsulated microenvironments present in cells, liberates proteases 
and phosphatases that are typically under tight regulation, and dilutes cell contents.123 Prior 
work has shown that cleavage location and degradation rate can differ between lysates and 
single cells31 and lysate experiments yield ensemble measurements that provide a population 
average, but do not allow discovery or interrogation of subpopulations. Therefore, in this 
work single cell analysis will be performed in addition to lysate experiments. 
1.4.2.1 Immunohistochemistry 
Developed in the 1930’s, immunohistochemistry (IHC) has a long history in disease 
diagnostics and basic research.124 IHC methods involve fixing and permeabilizing tissues 
before treating with antibodies directed against phosphorylated Akt (Ser473; considered 
active). Labeled tissues are examined by a highly trained pathologist, and the presence of Akt 
in tissue slices is visualized. This provides tissue localization information, but IHC is not 
quantitative and has garnered criticism for the subjectivity of result interpretation, since each 
pathologist has unique training.125 Most importantly, cells are fixed and permeabilized before 
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analysis, which terminates intracellular signaling by crosslinking intracellular proteins. This 
is troublesome when considering the timescales of chemical fixation, which may be 
significantly longer (seconds to minutes)126 when compared to the speed of kinase reactions 
occurring on the millisecond timescale.127 Therefore, there is a significant window of time 
available for cells to activate cell survival responses such as Akt during the fixation process, 
which may produce measurements artifacts or obscure accurate measurements of kinase 
activity.  
1.4.2.2 Western Blotting 
 The Western blot is the gold standard for identifying Akt in complex lysates from 
cells. Proteins in a sample are separated by molecular weight with gel electrophoresis before 
transferring the proteins to a solid support and labeling the kinase with a primary and 
secondary antibody.128 In many cases, phosphorylated Akt (Ser473) is also labeled with a 
phospho-specific antibody to assess the fraction of Akt that is active. Several thousand cells 
are required for such analyses, which also require significant amounts of costly antibodies.  
Recently, protein requirements have been miniaturized with the development of the 
single cell western blot (scWestern).129,130 The primary differences between the bulk and 
single cell method lie within the polyacrylamide gel utilized for protein separation. Rather 
than depositing microliters of sample into a slab gel several millimeters thick, scWesterns 
rely on a thin (30 µm) layer of polyacrylamide pockmarked with an array of microwells. 
Individual cells are loaded into wells, lysed, and single cell protein lysates are separated. 
Instead of the traditional transfer of proteins to a phosphocellulose support for detection, the 
thin gel is photopolymerized to immobilize proteins before probing with primary and 
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secondary antibodies. While promising, several limitations of the technology include 
crosstalk between microwells due to lysate diffusion out of microwells, physical overlap of 
proteins of interest within the short separation length of the miniaturized blot, and poor 
resolving power due to the short separation lanes.  
1.4.2.3 Genetically Encoded Fluorescent Sensors 
 Major innovations in molecular biology, in particular green fluorescent protein 
(GFP), have driven the development of genetically encoded intracellular fluorescent 
biosensors which can probe disease-relevant signaling pathways at the single cell level. 
Many of these sensors rely on the same principles as the fluorescent in vitro sensors 
described above. For example, Sasaki demonstrated that by flanking an Akt substrate and 
linker with two variations of GFP, phosphorylation by the kinase brought the GFP pair 
within the Förster radius, generating a fluorescent signal correlating with Akt activity.131 A 
similar reporter of Akt activity utilized a FOXO1 substrate which was expressed in a 
construct with the Cerulean/cpVenus fluorescent protein couple, which demonstrated the 
spatiotemporal dynamics of Akt activation by insulin. 106,132 Finally, the low signal-to-noise 
ratios observed with many genetically encoded sensors was improved through the 
development of a bioluminescent Akt reporter. The two domains of luciferase were 
connected by a Akt substrate, whose phosphorylation sterically constrained their association, 
thus preventing fluorescence. 133 
 Rather than employ a FRET pair, the Covert lab has developed a suite of kinase 
translocation reporters (KTRs) to assess kinase activity as reported by subcellular 
localization. Fluorescent kinase substrates were engineered with phosphorylation-sensitive 
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nuclear export or import sequences, converting kinase activity to localization changes. 134 
While a KTR has not been described for Akt, it was shown that the KTR technology is 
generalizable to several enzyme classes. The dynamic changes in JNK, p38, and ERK 
pathways in response to anisomycin were modeled with three KTRs.  
Overall, genetically encoded sensors enable real-time imaging of dynamic signaling 
events in single cells. They have direct applications in basic research and drug discovery. 
However, their utility is severely limited in clinical samples, which are often small and 
possess numerous cell types. This is rooted in the difficulties of uniformly transfecting 
primary cells, which can also induce significant stress to the cell and induce survival 
pathways such as Akt. Furthermore, genetically encoded sensors have notoriously low 
signal-to-noise ratios and may not accurately reflect the inactivation of the kinase by 
phosphatases, since the closed confirmation of FRET sensors is often highly stable and 
inaccessible to phosphatases. These encoded tools require rational design, optimization, and 
innovative delivery strategies, and in some cases, cell lines are the endpoint.  
1.4.2.4 Mass Cytometry 
The combination of features from flow cytometry and mass spectrometry led to the 
development of mass cytometry, which offers multiplexed single cell analysis of up to 120 
parameters, including the presence of Akt. Rare, nonbiological earth metals coupled to 
protein-specific antibodies are used as reporters.135 Cells are fixed and permeabilized before 
probing with antibodies and analysis with inductively coupled plasma-mass spectrometry 
(ICP-MS). The detected abundance of rare earth elements allows determination of protein 
marker expression in single cells. At an analysis rate of 2 million cells per hour, it is less 
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rapid than multi-color flow cytometry (25-60 million cells per hour) but boasts more than 
triple the multiplexing potential.136 Using mass cytometry, Han and others demonstrated that 
Akt was not upregulated as expected in some acute myeloid leukemia patients, but rather 
ERK was potentiating cell survival behaviors.137 The simultaneous analysis of nodes in 
multiple signaling pathways is inherently valuable to further understanding of pathway 
crosstalk in disease, but mass cytometry has several limitations. Since cells are fixed prior to 
analysis, it suffers from the same drawbacks as IHC in terms of potential measurement 
artifacts caused by fixation. Most importantly, it provides only an indirect gauge of kinase 
activity because Akt directed antibodies only measure Akt expression, not the comparative 
ratios of phosphorylated to native Akt substrates, whose relative amounts are key regulators 
of cell growth and apoptosis. It is also problematic to analyze small or rare populations of 
cells from clinical samples since the current technique of nebulizing single-cell droplets into 
the ICP-MS system is highly inefficient, with greater than 70% sample loss.136 For this 
reason, most analyses with mass cytometry have been conducted with blood cancers or other 
disorders where retrieval of approximately 104 cells is facile. 138 
1.5. Chemical Cytometry 
 Cytometry is simply defined as the characterization of individual cells. Chemical 
cytometry, defined by Dovichi in 2003, is the use of high sensitivity analytical 
instrumentation to characterize the components of individual cells.139,140 These are 
destructive assays which provide the opportunity to quantify and evaluate an ever-expanding 
number of compounds from a single cell, including nucleic acids, metabolites, and proteins. 
Inherent challenges with this type of analysis are twofold: i) small volumes associated with a 
single cell and ii) the limited mass or concentration of analytes. In the past, these challenges 
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were addressed by increasing the quantity of sample, with the rationale that the more material 
present, the greater the quantity of chemical entities to be detected. However, this is not 
necessarily true with heterogeneous populations. For example, if 0.1% of the cells in a tissue 
express a particular protein, then homogenization of the surrounding cells result in a 1000-
fold dilution of the compound of interest, while maintaining the concentration of compounds 
common to all cells.141 Thus, detection schemes for chemical cytometry must be adapted to 
the femtoliter volume and picogram protein content of a single cell. These span a wide array 
of technologies, including electrochemistry, mass spectrometry, and capillary electrophoresis 
(CE). 
Electrochemical detection of ascorbic acid from single protoplast cells has been 
accomplished by a microfluidic chip which allows single cell lysis and electrophoretic 
separation of lysates, but has relatively high detection limits.142 More recently, 
electrochemical detection has seen wide application in amperometric detection of 
neurotransmitters released from single cells via exocytosis.143,144 In order to access additional 
biological analytes without derivatization, other methods are preferred. Single cell analysis 
has been accomplished with mass spectrometry, which is well suited to discovery-driven 
research. Rather than measuring changes in selective probes, mass spectrometry methods 
forego a priori selection of analytes and instead the mass of all peptides, proteins, 
oligonucleotides and lipids within a selected mass range are detected. The development of 
“soft” ionization techniques which limit fragmentation, such as Matrix Assisted Laser 
Desorption Ionization (MALDI) and Electrospray Ionization (ESI) have significantly 
contributed to the detection of these biomolecules. For example, Onjiko et al. utilized single 
cell micro-ESI-CE to detect changes in 50 compounds in different localizations of a 16-cell 
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blastocyte.145 However, limitations of mass spectrometry lie primarily in the limited analytes 
which can be determined within existing detection limits, which mostly linger in the 
nanomolar domain. 146-148 Additionally, the ionization of some compounds may be more 
efficient than others into the mass spectrometer, complicating the quantification process. For 
these reasons, CE-based techniques with laser induced fluorescence detection (CE-LIF) are 
perhaps the most well-known methodology for chemical cytometry. CE is capable of 
physically separating the contents of an individual cell with very high resolution, peak 
capacity, and limits of detection in the yoctomole range.  
1.5.1 Principles of Capillary Electrophoresis 
CE is an analytical separation technique which resolves analytes based on their 
differential mobilities in an electric field. The seminal description of CE was published by 
Jorgenson and Lukas in 1981,149 and the technique has since seen wide application in 
biopharmaceutical, clinical, and environmental analyses. CE employs hollow, fused silica 
capillaries with small inner diameters (<150 µm) which are filled with electrolytic buffer. A 
sample is injected at the inlet, voltage is applied, and analytes are detected as they migrate 
past a detection window typically located near the outlet (Figure 1.2a). The migration 
velocity for a solute, specific for the ion and medium, is described in Equation 1.1. The 
effective mobility of the ion is the sum of its electrophoretic mobility (µep ) and the 
electroosmotic mobility of the electrolytic buffer (µeof ). 
The factors governing µep, , described in Equation 1.3 as a spherical analyte, includes 
the net charge, which is opposed by frictional forces due to the hydrodynamic radius of the 
analyte and the viscosity of the buffer (η). From this equation, it is evident that small, highly 
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charged molecules possess greater mobilities relative to large, minimally charged species. 
Neutral species have no inherent mobility in an electric field.  
Equation 1.1                                      𝑣 = µ𝑒𝑓𝑓𝐸 
𝑣 = migration velocity 
µeff = effective mobility 
E= electric field (V/cm) 
 
Equation 1.2                            µ𝑒𝑓𝑓 =  µ𝑒𝑝 + µ𝑒𝑜𝑓 
µeff = effective mobility 
µep = electrophoretic mobility 
µeof = electroosmotic flow mobility 
 
Equation 1.3                                µ𝑒𝑝 =  
𝑞
6𝜋η𝑎
 
q = net charge 
η = buffer viscosity 
a = hydrodynamic radius 
 
The surface charge, or zeta potential (ζ), of the capillary also plays a large role in CE. 
The fused silica surface possesses silanol groups (SiOH), which have pKa values ranging 
from 2.5 to 6 and can be ionized to their anionic form (SiO-) through pretreatment with 
base.150 The anionic surface results in the formation of an electrical double layer (Figure 
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1.2b). Cations, attracted from the bulk electrolyte, first form an adsorbed layer. This region, 
also known as the Stern layer, is immobile even in the presence of an electric field.151 
Beyond the Stern layer is a compact and mobile region occupied primarily by cations. 
Finally, the diffuse region, or Gouy-Chapman layer, extends past the mobile region. Beyond 
this electrical double layer (approximated at 100 Angstrom thickness) the zeta potential from 
the capillary wall is no longer sensed and the solution is effectively neutral. When a voltage 
is applied, the mobile cations near the wall migrate to the cathode. Since the ions are 
solvated, the bulk fluid in the Gouy-Chapman layer is dragged along as well. This 
electroosmotic flow (EOF; µeof ) extends past the thin electrical double layer, presumably 
through hydrogen bonding of water molecules, to establish a flow of buffer through the entire 
capillary. Smoluchowski first described the EOF in 1903 with Equation 1.4. 
Equation 1.4                                    µeof= 
ζε
4πη
 
µeof = migration of the electroosmotic flow 
ζ = zeta potential 
ε = dielectric constant 
η = buffer viscosity 
 
A key advantage of flow driven by electroosmosis rather than pressure is that it 
results in a plug-like, flat fluid velocity profile. When compared to the parabolic profile that 
arises in pressure driven flow due to interactions of the mobile phase with the tubing, 
electroosmosis results in increased separation efficiency. 152 Aside from enabling the EOF 
formation, the small diameter of the capillary has other advantages, including its high 
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electrical resistance which allows the application of very high electric fields (up to 500 
V/cm) with minimal heat generation. Additionally, the lack of a stationary phase in free zone 
electrophoresis (CZE) eliminates the resistance to mass transfer between stationary and 
mobile phases, the primary cause of band broadening in traditional liquid chromatography 
(LC). Under ideal conditions, longitudinal diffusion is the only source of band broadening in 
CZE. This leads to very high separation efficiencies, which is typically quantified as the 
number of theoretical plates (N; Equation 1.5). Separations with high plate numbers are 
considered to be more efficient, and CE separations are known to have unparalleled resolving 
power. Multiple groups have reported millions of theoretical plates for the separation of 
synthetic peptides. 153,154 
Equation 1.5                                     𝑁 = 5.545 (
𝑡𝑚
𝑤ℎ
)
2
 
N= number of theoretical plates 
𝑡𝑚 = migration time 
𝑤ℎ= peak width at half height 
 
The EOF is a crucial aspect of CE since it sweeps neutral molecules towards the 
detector, which do not migrate in an electric field. However, the separation of such neutral 
molecules is often difficult to achieve with CZE alone. Micellar Electrokinetic Capillary 
Chromatography (MEKC) is a hybrid method which utilizes both electrophoretic and 
chromatographic separation principles to separate neutral analytes. Surfactant molecules are 
added to the electrolytic buffer until micelles are formed, which act as a psuedostationary 
phase. When sodium dodecyl sulfate (SDS) is utilized as a surfactant, micelles possess a 
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hydrophobic core with a negatively charged outer shell. These micelles experience 
electrophoretic migration like any other charged particle in CZE, but they also interact with 
analytes through electrostatic and hydrophobic interactions.155 Owing to their negative 
charge, SDS micelles generally migrate against, albeit at a slower velocity than, the EOF 
when a positive voltage is applied, and thus are relatively late migrating. The dynamic 
partitioning that occurs with analytes, including neutral molecules, between large micelles 
and free solution provides an additional separation dimension that can distinguish between 
similar analytes. For example, chiral separations have been successful with MEKC owing to 
the affinity of the enantiomers towards the micelles.156 In general, the fraction of analyte 
incorporated into the micelle (nmc) versus the aqueous phase (naq) is modeled by the capacity 
factor (k’), similar to chromatography.  
Equation 1.6                                         𝑘′ =  
𝑛𝑚𝑐
𝑛𝑎𝑞
 
k’ = capacity factor 
nmc = fraction of the analyte incorporated into the micelle 
naq = fraction of the analyte in the aqueous phase 
 
The micelle partitioning process directly affects the resolution (R) for MEKC, which 
is given in Equation 1.7. MEKC separations have been performed with theoretical plate 
values as high as 900,000.157 These values are often lower than theoretical plates obtained 
with CZE since MEKC separations tend to be longer due to the later migrating micelles. 
Since longitudinal diffusion is the defining factor for efficiency, a shorter separation 
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produces higher efficiency. However, the increased resolution of neutral analytes granted by 
MEKC is often a welcome trade-off. For this reason, many of the peptide separations 
described in Chapters 2 and 3 of this dissertation were performed with MEKC.  
Equation 1.7              𝑅 =  
√𝑁
4
(
𝛼−1
𝛼
) (
𝑘2
′
1+𝑘2
′  
) (
1− 𝑡0 𝑡𝑚𝑐⁄
1+ (𝑡0 𝑡𝑚𝑐⁄ )𝑘1
′ ) 
N= theoretical plates 
α = separation factor 
𝑘1
′ = capacity factor for analyte 1 
𝑘2
′ = capacity factor for analyte 2 
𝑡0 = migration time for an analyte experiencing no interaction with micelles 
𝑡𝑚𝑐 = migration time for an analyte totally incorporated into micelles 
 
There are a variety of detection schemes which are compatible with both MEKC and 
CE including absorbance, fluorescence, photothermal refraction, amperometry, and 
conductivity.158 The most sensitive is laser induced fluorescence (LIF), in which fluorescent 
molecules are excited by a laser as they pass by the detection window. Since only fluorescent 
analytes are excited this technique boasts high selectivity and eliminates potential 
contaminants including assay components or cellular debris. LIF also has excellent limits of 
detection, with frequent reports of 10-21 moles or lower.159-161 
1.5.2 Using Peptides as Reporters of Kinase Activity 
 Short peptide sequences are simple to synthesize, relatively inexpensive, and highly 
customizable.162,163 When peptide substrates are based on known consensus sequences and 
possess the requisite amino acids for phosphorylation, they are useful tools for assessing 
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kinase activity. They can also be selectively labeled at the N-terminus with a fluorophore for 
detection with CE-LIF. Since both the native and phosphorylated versions of the peptide 
exhibit fluorescence, they can simply be separated by CE or MEKC to quantify the relative 
amounts of each. The Allbritton lab has extensive experience in the utilization of peptides as 
reporters of kinase164-170 protease,171-177 and phosphatase activity. 178,179 This dissertation will 
focus on the use of peptides as reporters for kinases and proteases.  
 One major challenge associated with peptides as intracellular kinase activity reporters 
involves their delivery to a single cell. Hydrophobic molecules such as steroids are lipid 
soluble and can enter the cell by passive diffusion across the plasma membrane, while most 
peptides cannot permeate the membrane. However, there are multiple existing methods for 
introducing macromolecules into living cells. Microinjection is an effective method for 
peptide delivery, but is extremely low throughput and requires skilled operators. Pinocytic 
loading, electroporation, and optoporation have also been utilized to introduce peptides into 
cells.180-183 While these methods are useful for high throughput peptide loading, they can 
induce significant cellular stress that may activate the survival pathways and artificially 
increase the kinase activity measured, obscuring accurate measurements of normal versus 
aberrant enzyme activity. Cell permeable peptides such as HIV-TAT and octoarginine have 
also been reported, but often result in endocytic uptake which can prevent the reporter from 
interacting with cytosolic enzymes such as Akt.184-186 Chemical innovations to overcome 
such peptide delivery challenges are described in Chapter 3.  
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1.5.3 Single Cell Capillary Electrophoresis 
 Capillary electrophoresis was first utilized to analyze the contents of individual cells 
in a series of publications by Jorgenson et al, the same group known for the formative 
publications on CZE. In all cases, giant neurons were the cells of interest. Individual cells 
were homogenized and their contents injected into a CZE system. Molecules possessing 
primary amines were labeled with naphthalene-2,3-dicarboxyaldehyde (NDA) for 
fluorescence detection.187,188 This enabled the identification of tryptophan, tyrosine, and 5-
hydroxytryptophan (5-HT) from a single cell lysate. By 1994, Jorgenson had partnered with 
Wightman to detect intracellular and excreted catecholamines from single neurons. 189,190 
There have since been significant developments in analysis of compounds from individual 
cells from countless cell types, including primary cells. A large number of proteins have been 
identified by utilizing a two-dimensional capillary sieving electrophoresis separation 
combined with MEKC.191 However, a large remaining challenge associated with single cell-
CE is the low throughput. Often up to 15 cells can be manually analyzed with CE per day, 
owing to the serial nature of analysis, manual positioning of the capillary, and the challenges 
with delivering reporters to cells. Dovichi has improved throughput for single cell analysis 
with a multiplexed array of up to 5 capillaries which can simultaneously sample the contents 
of single cells.192 Microfluidic platforms also require mention since they are capable of 
analyzing hundreds of cells per hour, but their use is often limited to nonadherent cell 
types.172,193 Recently, Dickinson et al reported a fully-automated CE system capable of 
analyzing 3.2 cells per minute, rivaling microfluidic devices and providing the robust 
separations of a capillary-based method. 194  
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1.6 Scope of Dissertation 
 The following chapters of this dissertation will describe the development and 
characterization of an assay for measurement of Akt activity in single cells utilizing chemical 
cytometry. Chapter 2, which is submitted as a manuscript to Analytical Chemistry, describes 
the characterization of Akt activity in FLS from healthy subjects as well as those suffering 
from RA. Chapter 3 will discuss the photochemical modification of an Akt peptide reporter, 
resulting in improvements in the throughput of enzyme activity measurements in pancreatic 
cancer cells when paired with an automated, high throughput CE system. This chapter is in 
preparation to be submitted as a manuscript to Angewandte Chemie International Edition. 
Chapter 4 describes preliminary work on the development of a degradation-resistant Akt 
reporter through a rational design strategy. In chapter 5, methodology to track peptide 
metabolism in individual cells will be described. This chapter has been published in 
Analytical Chemistry.195  
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1.7 Figures 
 
Figure 1.1 A simplified schematic of Akt (aka PKB) activation. Akt can be 
stimulated by binding of growth factors, cytokines, and other ligands which activate PI3K. 
Akt is recruited to the membrane where it is partially activated by PDK1 (at T308) and fully 
activated by phosphorylation at S473. Active Akt diffuses away from the membrane to 
phosphorylate its downstream targets.  
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Figure 1.2 Capillary electrophoresis.  A) Schematic of a CE system. The capillary is 
submerged in buffer while a high voltage is applied. Analytes reach the detection window, 
where they are interrogated with a 488 nm solid state laser. Emission at 530 nm is detected 
with a photomultiplier tube before processing with a Digital-to-Analog Converter (DAQ) and 
output onto a computer. B) Formation of the electrical double layer required for 
electroosmotic flow (EOF).  
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Chapter 2: Single Cell Chemical Cytometry of Akt Activity in Fibroblast-like 
Synoviocytes Reveals Heterogeneity in Responses of Rheumatoid Arthritis Subjects to 
Tumor Necrosis Factor α 
 
2.1 Overview 
The etiology of rheumatoid arthritis (RA) is poorly understood, and 30% of patients 
are unresponsive to established treatments targeting Tumor Necrosis Factor α (TNFα). Akt 
kinase is implicated in TNFα signaling, and may act as a barometer of patient responses to 
biologic therapies. Fluorescent peptide sensors and chemical cytometry were employed to 
directly measure Akt activity as well as proteolytic activity in individual fibroblast-like 
synoviocytes (FLS) from RA and normal subjects. The specificity of the peptide reporter was 
evaluated and shown to be a valid measure of Akt activity in single cells. The effect of TNFα 
treatment on Akt activity was highly heterogeneous between normal and RA subjects, which 
was not observable in bulk analyses. In 2 RA subjects, a bimodal distribution of Akt activity 
was observed, primarily due to a subpopulation (21.7%: RA Subject 5 and 23.8%: RA 
Subject 6) of cells in which >60% of the reporter was phosphorylated. These subjects also 
possessed statistically elevated proteolytic cleavage of the reporter relative to normal 
subjects, suggesting heterogeneity in Akt and protease activity that may play a role in the 
RA-affected joint. We expect that chemical cytometry studies pairing peptide reporters with 
capillary electrophoresis will provide valuable data regarding aberrant kinase activity from 
small samples of clinical interest. 
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2.2 Introduction 
The advent of biologic therapies for treatment of rheumatoid arthritis (RA) signaled a 
shift towards precision medicine for treatment of rheumatologic disorders. Three very 
successful RA biologics include etanercept, adalimumab, and infliximab, all targeting TNFα, 
an inflammatory cytokine commonly upregulated in RA.1 Though considered revolutionary, 
these engineered proteins yield no clinically measurable benefit in 30% of patients; coined 
‘primary nonresponders’.2 Due to the cost and potential co-morbidities associated with these 
drugs, the rheumatology community has worked for over a decade to identify biomarkers 
which may be predictive of patient response to anti-TNFα therapies. Clinical factors such as 
sex, smoking, and the presence of anti-cyclic citrullinated peptide antibodies as well as TNFα 
itself have not been predictive of patient response to anti-TNFα biologics; thus, the focus has 
shifted towards identification of molecular biomarkers or biochemical response profiles.3 
One potential biomarker is the serine/threonine protein kinase Akt (also called protein 
kinase B), which is downstream of the TNFα receptor and is a component of TNF 
biochemical signaling. Both upregulated expression4 and constitutive activation5-7 of Akt in 
FLS have been linked to chronic inflammation, increased efflux of matrix metalloproteinases 
(MMPs), and resistance to apoptosis, resulting in pseudo-tumoral proliferation of FLS and 
the irreversible cartilage damage characteristic of RA. These Akt abnormalities appear to 
exist primarily in FLS rather than macrophages or other cell types, suggesting that overactive 
Akt in FLS may be a component of disease progression.7 Thus, this signaling arm is being 
pursued as a therapeutic target for novel therapies and inhibitors with anti-inflammatory 
effects.8 With Akt mediating multiple downstream effects of TNFα signaling, the 
biochemical activity of this kinase in cells may also act as a barometer of the downstream 
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effects of upregulated TNFα, with potential applications in patient classification as anti-
TNFα therapy responsive or non-responsive.  
 A complicating factor in the analysis of these cells is the heterogeneity expected in 
RA FLS that possess this aggressive phenotype.9 Since only a fraction of the FLS population 
may have aberrant Akt activity, with even fewer present at early stages of the disease, it 
becomes imperative to analyze these cells with single-cell resolution. Traditional 
methodologies to determine the presence of Akt, such as immunohistochemistry, are valuable 
in determining the location of the kinase in tissue, but they are generally qualitative and do 
not provide compelling evidence that the labeled kinase’s biochemical activity is aberrant.10 
Western blotting is another useful technique to garner gene expression information, but the 
detection of distinct subpopulations is not possible as the blot returns an ensemble average of 
the bulk population. Moreover, it is often difficult to obtain sufficient cells in biopsy samples 
for assay performance. Hughes and co-authors demonstrated a multiplexed solution capable 
of single-cell Western blots11, but the nature of their antibody-based kinase detection did not 
allow detection of constitutively or transiently active enzymes through quantification of 
substrate and products. These protein-only detection schemes are the primary limitations of 
other single-cell techniques, including Phospho-flow and mass cytometry.12,13 Liquid 
chromatography coupled tandem mass spectrometry (LC-MS/MS) has been reported to more 
accurately measure the stoichiometry of Akt phosphorylation in biological samples, but it 
requires immunoprecipitation, resulting in substantial samples losses.14 Furthermore, the low 
sensitivity necessitates large sample sizes. Meaningful measurement of Akt activity within 
RA FLS instead requires single-cell resolution, excellent limits of detection, quantification of 
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substrate and products (as well as differentiation between any additional metabolites) and 
head-to-head comparison with normal FLS cells. 
 Chemical cytometry in the form of capillary electrophoresis with laser induced 
fluorescence detection (CE-LIF) routinely attains excellent (10-20 mol) limits of detection, as 
is required when analyzing intracellular metabolites of single mammalian cells which are 
typically ≤1 pL in volume. When coupled with peptide based probes, this separation based 
technology can directly assess kinase activity15-17, and is highly quantitative with the 
inclusion of internal standards. In this study we performed the first evaluation of Akt and 
peptidase activity in single FLS cells with direct comparison to normal controls. Prior to 
single-cell analysis, the specificity of the peptide based Akt reporter was characterized to 
ensure rigorous measurements of the intended pathway. The Akt activity was then quantified 
in single cells from normal and RA FLS cells by chemical cytometry, and compared to 
traditional bulk analyses, which revealed novel information about the heterogeneity of this 
pathway in RA FLS.  
2.3 Materials and Methods 
2.3.1 Cell Culture 
Hela (human cervical cancer) and OPM2 (human multiple myeloma) cell lines were 
obtained from the American Type Culture Collection and maintained in a humidified 
atmosphere of 37°C in 5% CO2. Hela cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), penicillin (100 
units/mL) , and streptomycin (100 µg/mL), while OPM2 cells were maintained in RPMI-
1640 media with the same supplements. 
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2.3.2 FLS Cell Culture  
FLS from 6 individuals were collected at the time of synovectomy or total joint 
replacement. Three were biologic-naïve RA patients which fulfilled the American College of 
Rheumatology 1997 criteria for RA classification. Three were individuals who were 
undergoing surgical resection of tissue for reasons unrelated to rheumatologic disorders. 
Tissues were stored under liquid N2 until the time of FLS culture. Synovial tissue was 
minced and immobilized in a tissue culture plate and covered with Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% 
PenStrep Solution (Gibco, Grand Island, NY) and were maintained in a humidified 
atmosphere of 37°C in 5% CO2. Media was changed regularly until the FLS expanded to fill 
the entire plate. These cell lines from primary FLS were utilized from the third to ninth 
passage.  
2.3.3 Small Interfering RNA transfection in FLS 
Akt and scrambled non-targeting siRNA were purchased from Dharmacon Research, Inc. 
(Lafayette, CO, USA). The FLS cells were seeded in culture plates and grown to 80% 
confluence. FLS cells (3 x 105) were transfected with a variety of siRNA concentrations 
utilizing the Amaxa Human Dermal Fibroblast Nucleofector kit (NHDF-adult) with high 
efficiency program U-023 for human cells. After transfection, cultures were incubated at 
37°C for 12 h and then placed in fresh culture media. Forty eight hours after transfection, the 
cells were harvested and the Akt protein expression levels were determined by Western blot 
analysis.  
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2.3.4 Western Blot Analysis 
FLS from normal or rheumatic human samples were obtained and cultured. Cells were 
either not stimulated or stimulated with 100 nM TNFα for 30 min and then lysed in ice cold 
RIPA buffer plus protease and phosphatase inhibitors (10 mM Tris-Cl (pH 8.0), 1 mM 
ethylenediaminetetraacetic acid (EDTA), 0.5 mM ethyleneglycoltetraacetic acid (EGTA), 1% 
Triton X-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 140 mM 
NaCl, 1X cOmplete ULTRA Protease Inhibitor and 1X PhosSTOP Phosphatase Inhibitor 
Cocktail (Roche, Indianapolis, IN)). Protein lysates were normalized using a BCA assay 
(Thermo Scientific, Rockford, IL) and run on a Mini-PROTEAN TGXTM gel (Any kDTM, 15-
well comb, 15 µl) (Bio-Rad, Hercules, CA). Between 6-10 µg total protein was run per 
independent experiment. All lysates for an independent experiment were run on the same blot 
for direct comparison of signaling strength. Antibodies were from Cell Signaling Technology 
(Danvers, MA) or Trevigen (Gaithersburg, MD): P-Akt (S473) (D9E) XP® Rabbit mAb), 
anti-G3PDH/GAPDH, Akt Rabbit Ab, and anti-rabbit IgG, HRP-linked Antibody. All 
antibodies were diluted in 1x Tris-Buffered Saline with Tween 20 (Cell Signaling, Danvers, 
MA) + 3% Bovine Serum Albumin (BSA). Images were scanned and imported into ImageJ 
where images were converted into an 8-bit black and white image. 
2.3.5 Cell Loading and Single-Cell Analysis by Capillary Electrophoresis 
FLS from normal and rheumatoid arthritis subjects were separately cultured in 
custom cell chambers as described previously.18 Chambers were placed on the stage of a 
custom-built single-cell CE-LIF system (fluorescence excitation at 473 nm, emission at 530 
nm).19 Cells were microinjected with 100 µM peptide VI-B (6FAM-GRP-MeArg-AFTF-
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MeAla-Amide) using a Transjector 5246 microinjection system (Eppendorf AG, Hamburg, 
Germany) and bathed in a continuous flow of extracellular buffer (ECB; 10 mM HEPES, 135 
mM NaCl, 5 mM KCl, 1 mM CaCl2, pH 7.4, 37°C) during incubation and analysis. After 
microinjection (5 min), individual cells were rapidly lysed with a 9 ns pulse from a Nd:YAG 
laser (New Wave Research, Bozeman, MT) and the cellular contents simultaneously 
electrokinetically injected (5 s at -125 V/cm) into an overlying 30 µm inner diameter 
(Polymicro Technologies, Phoenix, AZ). Electrophoresis was performed in 100 mM borate, 
15 mM SDS, pH 11.6 with a field strength of -250 V/cm. Electropherograms were integrated 
using customized software written in MATLAB (Natick, MA).17 Detailed information 
regarding peptide fragment nomenclature and identification is available in supplemental 
information. 
2.3.6 Identification of Peptide Fragmentation Products 
Synthetic standards of all possible fluorescent peptide fragments of VI-B were 
synthesized as described previously.2 Under the electrophoretic conditions used, the 
phosphorylated peptide was fully resolved from the parent peptide and each potential 
fragment. Thus, the fragments formed and their identities were identifiable as described 
previously.2 Each peak present in the individual cells were readily matched by migration time 
to a fluorescent peptide fragment or the intact or phosphorylated reporter.  
2.3.7 Flow Cytometry 
Antibodies conjugated with AlexaFluor 647 (AF647) were utilized for flow 
cytometry. CD120a (Tumor Necrosis Factor Receptor 1)–AF647 and isotype control 
immunoglobulin (Ig)G2a-AF647 were purchased from BioRad (Hercules, CA). For washes, 
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incubation and data acquisition, cells were suspended in incubation buffer (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 20 mM 4-(2-hydroxyethyl)-1-
piperzineethanesulfonic acid, 5 mM EDTA, 2% FBS). FLS cells were removed from tissue 
culture dishes with Accutase (Sigma Aldrich, St. Louis, MO) per manufacturer's instructions. 
CD120a-AF647 antibody and 500 nM SYTOX Green (ThermoFisher Scientific, Waltham, 
MA) was added to FLS cells (0.1 µg/mL) and incubated for 30 min in the dark at 25°C. Cells 
were washed twice with incubation buffer by centrifugation at 300 x g for 5 min. For an 
isotype control, FLS cells were stained with (Ig)G2a-AF647 (0.1 µg/mL) and 500 nM 
SYTOX Green. Positive control staining was performed with HeLa cells. Data were acquired 
on a FACSAria II Flow Cytometer (BD Biosciences, San Jose, CA) and analysis was 
performed using BD FACSDiva 8.0 software.  
2.3.8 Statistical Analysis  
To analyze single cells in these chemical cytometry experiments, the distribution of 
the difference between the mean percentage of phosphorylated peptide or intact full length 
reporter in each single-cell analysis treatment and control group was calculated utilizing 
bootstrapping.20 10,000 bootstrap replicates (with replacement) were generated from each 
group and the means of each bootstrap replicate group were calculated. The distribution of 
the differences between the appropriate pairs of bootstrap replicates was utilized to estimate 
the distribution of the mean differences. The p-value for testing the null hypothesis of no 
difference in mean between the control and treatment groups was estimated by dividing the 
number of bootstrap differences which possessed values of 0 or less by the number of 
bootstrap replicates (10,000).  
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Boxplots were utilized to represent the non-normal distribution of the reporter 
phosphorylation from individual cells. Within the boxplots, squares represent the mean value 
from all cells. The middle bar indicates the median, while the upper and lower boxes showed 
the 75% and 25% percentile of the data, respectively. Whiskers extend to the 5th and 95th 
percentiles. Any individual data points outside of the whiskers are outliers. 
2.4 Results and Discussion 
2.4.1 Evaluating Peptide Reporter Specificity 
In order to measure Akt activity in single FLS, a phosphorylatable-threonine-
containing peptide, herein after referred to as VI-B (6FAM-GRP-MeArg-AFTF-MeAla-
Amide), was utilized. The sequence was determined using an iterative design strategy 
originating from the consensus sequence of Akt.16 VI-B possessed favorable phosphorylation 
kinetics as well as demonstrated degradation resistance, and has been employed to measure 
Akt activity in single tissue-cultured cells and pancreatic adenocarcinoma patient-derived 
xenografts.21,22  
Since many eukaryotic protein kinases possess similar catalytic domains,23 we sought 
to evaluate whether the majority of VI-B phosphorylation was due to Akt or other analogous, 
potentially interfering kinases. A basal level of phosphorylation was established by depriving 
FLS cells of serum for 12 h, loading VI-B, and analyzing cells by single-cell CE-LIF. Basal 
phosphorylation varied between cells (0-37%), but was similar between normal and RA 
subjects (p = 0.31) (Figure 2.1A,B). To determine whether VI-B phosphorylation was a result 
of Akt activity or due to other kinases within the intracellular environment, reporter 
phosphorylation in response to physiologic stimulation or pharmacologic inhibition of the 
Akt pathway was measured. Insulin stimulates cell growth and protein synthesis by 
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activation of Akt.24 When FLS were treated with 100 ng/mL insulin, significantly increased 
mean VI-B phosphorylation was observed in both normal (n = 16; 38.2 ± 31%) and RA 
subjects (n = 11; 39.5 ± 37.7%). Conversely, when cells were treated with 10 µM LY294002, 
a reversible inhibitor of PI3K, the kinase directly upstream of Akt,25 mean VI-B 
phosphorylation was less than 5% of the basal level. These data supported that the majority 
of the reporter phosphorylation observed was the result of Akt activity (Figure 2.1A,B).  
 In a second experiment, Akt protein was transiently knocked down in FLS by 
administering a specific siRNA for Akt. The presence of the kinase was monitored 48 h post 
siRNA-transfection by western blot (Figure 2.1C), which demonstrated a dose-dependent 
reduction in Akt expression. The transfection process did not disrupt Akt expression, as 
demonstrated by similar expression of Akt between un-transfected cells (0 nM Akt siRNA) 
and 500 nM of a non-targeting (NT) scrambled siRNA. Using chemical cytometry, VI-B 
phosphorylation was assessed in single cells 48 h following transfection with 300 and 500 
nM Akt-targeting siRNA. Cells were serum starved and stimulated with insulin (100 ng/mL) 
prior to analysis as described above. Significant reduction in reporter phosphorylation was 
seen in comparison to FLS transfected with non-targeting scrambled siRNA (Figure 2.1D), 
again supporting that a dominant portion of reporter phosphorylation was due to Akt activity. 
These data from physiologic and pharmacological perturbation of the Akt pathway indicated 
that VI-B phosphorylation was a valid measure of Akt activity in FLS.  
2.4.2 Akt Activity within Single FLS from RA and Normal Subjects 
Individual FLS cells (analyzed: n=107) were stimulated with TNFα to determine 
whether this factor would activate Akt in FLS from normal and RA subjects (Figure 2.2). 
TNFα is known to be elevated in the joints of RA patients; therefore, addition of TNFα to 
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FLS is expected to partially mimic the inflammatory environment of the RA-affected joint. 
FLS obtained from RA patients and normal subjects were plated on glass cell chambers. 
Cells were serum-starved overnight, then stimulated with 100 ng/mL TNFα for 30 min and 
loaded with VI-B. After a 5-min incubation, individual cells were assayed for 
phosphorylation of VI-B. When cells originating from normal subjects 1-3 (N1-N3) were 
stimulated with TNFα, minimal phosphorylation of the reporter was detected (Figure 2.2D). 
N1-N3 demonstrated 0.8±2.5% (n=14), 1.6±6.1% (n=16), and 0.8±2.6% (n=15) 
phosphorylation, respectively (Figure 2.3B). When individual FLS were analyzed from RA 
Subject 4 under identical conditions s (Figure 2.3A), a similar level of phosphorylation was 
detected (0.5±2.1% [n=18]), suggesting that in this particular subject, TNFα contributed 
minimally to Akt activation. In contrast, when single FLS were analyzed from RA subjects 5 
and 6, the mean phosphorylation rose to 25.6±36.4% (n=23) and 27.1±37.8% (n=21), 
respectively. This was primarily due to a subpopulation (21.7% of cells: RA Subject 5 and 
23.8% of cells: RA Subject 6) which phosphorylated >60% of the reporter within the 5 min 
incubation period.  
2.4.3 Active Akt Determined by Western Blot Analysis in Lysates from FLS 
Western blot analysis was performed on FLS from all subjects to compare the amount 
of active Akt detected between single cells and ensemble population level measurements 
(Figure 2.3C). Cells were unstimulated or stimulated with TNFα as described above prior to 
lysis. The amount of endogenous Akt was determined with an anti-Akt antibody competent 
to bind to Akt1, Akt2, and Akt3. Phospho-Akt was estimated utilizing a monoclonal antibody 
against phosphorylated serine at location 473. In all cases, TNFα treatment resulted in 
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increased amounts of p473, but there were no differences detectable between normal and RA 
subjects. 
2.4.4 Tumor Necrosis Factor Receptor 1 (TNFR1) Expression in FLS 
TNFα signaling is initiated by binding to receptors expressed on nucleated cells. Of two 
distinct receptors, Akt is thought to be regulated by the 55-kDa type 1 receptor (TNFR1).8 To 
evaluate whether differences in TNFR1 expression between RA and normal subjects might 
be due to receptor expression, we probed FLS with antibodies specific for the receptor and 
analyzed the FLS by flow cytometry (Figure 2.4). Positive, negative, and isotype controls 
were also performed (Figure 2.5). Cells were concomitantly stained with SYTOX green (50 
µM) to detect non-viable cells. All subjects possessed TNFR1 positive populations with few 
TNFR1-negative cells. Statistical analysis (Kruskal Wallis one-way ANOVA) performed on 
live cells determined TNFR1-positive revealed that normal subjects 2 and 3 possessed 
elevated expression of TNFR1 (p = 0.009 and 0.012, respectively), relative to RA cells. This 
is in agreement with reports of decreased membrane TNFR1 expression on RA FLS, which 
may occur due to receptor internalization or to increased rates of cleavage of membrane 
TNFR1 to form soluble extracellular 17 kDa TNFα, not detected by flow cytometry.26-28 The 
mechanism of Akt activation in cells with decreased TNFR1 expression remains debated, but 
it is possible that the increased TNFα ligand generated by cleavage of the receptor,29 or that 
shuttling of TNFα by the soluble receptor7 plays a role.  
2.4.5 Degradation of VI-B in Single FLS from Normal and RA Subjects 
It is well known that within the RA-affected joint, FLS secrete potent MMPs and 
cathepsins which act extracellularly to degrade collagen and bone.9 Intracellular protease and 
peptidase activity constitutes a mostly unexplored area of FLS research, but correlations have 
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been shown between advanced (>10 yr duration) RA and highly active intracellular 
proteolysis pathways involving cysteine and aspartate proteinases.30 As shown in Figure 
2.2A,F, we generated standards of all potential fluorescent fragments of VI-B, which are 
well-resolved from phosphorylated VI-B by CE-LIF. Thus, we have the capability to identify 
the fluorescent proteolysis products of VI-B via chemical cytometry as previously 
described16, and therefore characterize the proteolysis rate as well as the primary sites of VI-
B cleavage within FLS from RA as well as normal subjects. Normal subjects 1-3 and RA 
Subject 4 possessed similar (p = 0.11) rates of VI-B degradation (Figure 2.6A,B): 0.14±0.76, 
0.35±0.78, 0.75±0.46, and 0.71±.69 zmol pg-1 s-1 for Subjects 1-4, respectively. However, 
RA Subjects 5 (2.99±0.52 zmol pg-1 s-1) and 6 (3.27±0.60 zmol pg-1 s-1) demonstrated 
significantly more rapid degradation of the reporter (p = .013), providing evidence that at 
least some RA subjects have significantly greater proteolytic capability, which may correlate 
with intracellular Akt activity. 
 Interestingly, fragment identities between RA and normal cells also differed (Figure 
2.6C,D). Fragment F1 corresponds to the shortest possible fluorescent fragment (6FAM-G), 
which extends C-terminally to the longest fragment F8 (6FAM-GRP-MeArg-AFTF). RA 
Subjects 5 and 6 were the only group to cleave between phenylalanine and threonine (F6), 
with an average frequency of 19.4±5.8% (RA5) and 22.5±9.8% (RA6). Both RA and normal 
subjects often possessed the fragments arising due to cleavage C-terminal of arginine (F2) 
and N-methylarigine or alanine (F4/5) (RA: 52.2±22% Normal: 46.6±14%). RA Subjects 
rarely produced fragments due to cleavage after proline (F3), penultimate phenylalanine (F7), 
or glycine (F1), which were frequently observed in small quantities from the FLS of normal 
subjects (Figure 2.6D, F).  
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2.5 Conclusions 
While prior reports have indicated that Akt activity can be elevated in RA FLS cells 
in response to TNFα,31 this is the first demonstration of the heterogeneity of this response, 
both within and between RA subjects. Such differential upregulation of Akt between patients 
may indicate differences in the responsiveness of the Akt pathway in these cells, for example, 
in the ability to transmit the downstream signal after TNFα binding to modify cell behavior, 
i.e. apoptosis resistance and/or secretion of MMPs.32 With respect to the heterogeneity of Akt 
activity within RA Subjects 5 and 6, such cell-to-cell variation in Akt activity is not 
unprecedented in the literature; it is relatively common in cancers33, Proteus syndrome34, and 
other diseases35,36 that hijack this pathway to promote survival of cells under stressful 
conditions. Importantly, bulk analyses by western blotting was unable to resolve these 
differences in activation, solidifying the concept that single cell analysis is necessary to 
observe the intra- and inter-subject heterogeneity in Akt signaling upon TNFα stimulation. 
It was also determined that RA subjects 5 and 6 possessed more rapid degradation of 
the reporter and that fragmentation occurred in locations not detected in normal subjects. It is 
possible that these findings are due to the differential activity and/or different types of 
proteases or peptidases found in FLS of RA and normal subjects. For example, the protease 
cathepsins B and L are known for their role in extracellular degradation of collagen, but are 
also overexpressed intracellularly as a result of increased TNFα stimulation.37,38 Specificity 
studies indicate their canonical preference for aromatic residues including phenylalanine.39 
The increased cleavage at hydrophobic residues (F6) observed in RA subjects 5 and 6 could 
potentially be due to contributions from such cathepsins B and L.  
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FLS cells within the RA afflicted joint are unique in their dependence on kinases such 
as Akt, which allow for unfettered growth, but also proteases, which catalyze the destruction 
of cartilage, therefore the simultaneous measurement of both these parameters may be 
clinically valuable. Tracking the Akt upregulation within single cells from many RA patients 
following treatment to inhibit TNFα should help inform our understanding as to whether the 
activity of this kinase might be a predictive marker of patient response to biologic therapies. 
Importantly, cells possessing elevated Akt and protease activity could be identified in 
difficult-to-analyze small clinical samples, such as a fine needle biopsy or synovial fluid 
collection40; samples that current methodologies struggle to analyze.  
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2.6 Figures and Tables 
 
Figure 2.1 Specificity Evaluation of Akt Reporter VI-B. Basal measurements, physiologic 
stimulation, and pharmacologic inhibition of the Akt pathway in single FLS cells from a A) 
normal subject 1 or B) RA subject 5. Before microinjection with VI-B, cells were either 
serum starved for 12 h for basal measurements, stimulated with 100 ng/mL insulin, or were 
treated with 10 µM LY294002 prior to insulin treatment (100 ng/mL). C) Western blot 
results from siRNA knockdown of Akt in RA Subject 5. The housekeeping protein GAPDH 
was probed as a loading control. Cells underwent no transfection as a control or were 
transfected with various concentrations of Akt-targeting siRNA or non-targeting, scrambled 
siRNA (NT siRNA). D) Individual FLS cells analyzed for Akt activity 48 hrs after siRNA 
transfection with Akt-targeting siRNA or non-targeting, scrambled siRNA (NT siRNA).  
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Figure 2.2 Akt Activity Measurements in Single FLS. CE-LIF analysis from individual 
cells originating from RA subject 5 (A,C,E) and normal subject 1 (B,D,F). Migration time 
standards of parent peptide (VI-B), phosphorylated peptide (P) and all possible fluorescent 
fragments (F1-8, Table 2.1) were loaded into the capillary after loading the contents of single 
cells not loaded with VI-B (A,B). Individual cells were stimulated with 100 ng/mL TNFα for 
30 min (C,D) or treated with 10 µM LY294002 for 25 min prior to TNFα stimulation (E,F) 
and subsequently analyzed with CE-LIF. Each trace represents CE-LIF analysis of a single 
cell. 
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Figure 2.3 Akt Activity in FLS from Normal and RA Subjects after Stimulation with 
TNFα. Each data point represents a single cell analyzed for Akt activity from A) RA subjects 
or B) normal subjects. All cells were serum deprived overnight and subsequently stimulated 
with 100 ng/mL TNFα for 30 min before analysis with chemical cytometry. C) Western 
blotting was performed in lysates prepared from cells with and without TNFα stimulation 
(100 ng/mL).  
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Figure 2.4 Tumor Necrosis Factor Receptor 1 (TNFR1) Expression in FLS. Normal 
subjects 1-3 (N1-N3, dashed lines) and RA subjects 4-6 (RA4-6, solid lines) FLS were co-
stained with a monoclonal antibody to detect TNFR1 and the dead-cell indicator SYTOX 
Green (10 µM), then were analyzed by flow cytometry. TNFR1 positive, viable cells are 
depicted to the right of the arrow and possess a minimum relative fluorescence intensity of 
1500.  
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Figure 2.5. Analysis of FLS Cells by Flow Cytometry. Tumor Necrosis Factor Receptor 1 
(TNFR1) positive, viable cells are present in the right hand lower quadrant (Q3) of each cell 
density plot A) Isotype control antibody IgG2a-AF647 was incubated with RA Subject 6 
cells prior to analysis, demonstrating minimal nonspecific binding. B) HeLA cells stained for 
TNFR1 C) OPM2 cells stained for TNFR1 D-F) Normal subjects N1-N3 and G-I) RA 
subjects RA4-6 were stained for TNFR1. All cells we co-stained with SYTOX Green to 
identify nonviable cells.  
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Figure 2.6 Proteolysis of VI-B in Single FLS cells from Normal and RA Subjects. 
Histograms illustrating the percentage of intact, un-degraded reporter (VI-B) from each 
TNFα-stimulated cell analyzed by chemical cytometry from A) normal and B) RA subjects. 
Fragmentation profiles for C) normal subject 1 (n=14 cells each depicted as a different color) 
and D) RA subject 5 (n=23). VI-B represents the full length peptide, while F1-F8 indicates 
the 1 to 8 amino-acid fluorescent fragments, respectively. Fragment identities can be found in 
Table 2.1. 
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Table 2.1 Fragment nomenclature for reporter VI-B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Proteolytic Fragment 
F1 6FAM-G-OH 
F2 6FAM-GR-OH 
F3 6FAM-GRP-OH 
F4 6FAM-GRP-MeR-OH 
F5 6FAM-GRP-MeR-A-OH 
F6 6FAM-GRP-MeR-AF-OH 
F7 6FAM-GRP-MeR-AFT-OH 
F8 6FAM-GRP-MeR-AFTF-OH 
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Chapter 3: Cell Permeable, Photoactivated Peptide Reporters: Shining a Light on Akt 
Activity in Single Cells 
 
3.1 Overview 
 Akt kinase is a known contributor to tumor formation, and tools to evaluate the 
activity of this kinase in small clinical samples may eventually guide precision medicine. 
Microinjected or genetically encoded peptide sensors are powerful tools to detect aberrant 
kinase activity, but generally preclude high-throughput studies with primary cells. To address 
these limitations, we developed a cell permeable, photoactivated peptide reporter which can 
be delivered en masse to a population of cells. Since the 2-4,5-dimethoxy 2-nitrobenzyl 
(DMNB)-caged probe becomes active upon light stimulation, it enables programmable 
reaction times. We demonstrated that this strategy may be generalizable, and when paired 
with an automated capillary electrophoresis analysis system, significant improvements in 
throughput are achieved while retaining the ability to quantify all fluorescent metabolites 
from single cells.  
3.2 Introduction 
Protein kinases are arguably the largest driver of intracellular signal transduction. When 
regulatory control of this family of enzymes is usurped by disease, the relative amounts of 
phosphorylated product and substrate become unbalanced. This is true of protein kinase Akt 
aka protein kinase B, whose dysregulation is a key step in tumor formation and 
maintenance.1 As such, this enzyme and the pathway (phosphoinositide 3-kinase (PI3K)) to 
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which it belongs are targets for therapeutics and companion diagnostics. Selection of patients 
for treatment with Akt inhibitors will rely on development of analytical platforms to identify 
aberrant kinase activity in clinical samples, but this remains a challenge due to the small 
tumor sample sizes attainable and their mixed cellular composition. Single cell analysis is 
necessary due to the presence of rare subpopulations which may be masked in bulk analysis 
only to drive drug resistance at a later point.2  
Fluorescent peptide reporters have been utilized as reporters to directly assess kinase 
activity, and stand to bridge the gap between small molecules which are poor substrates and 
of limited specificity and genetically engineered proteins which often preclude use with 
primary and other difficult to transfect cells.3,4 Peptide reporters are phosphorylated by 
kinases within intact cells and the relative ratios of unphosphorylated peptide and 
phosphorylated product obtained from single cells is quantified by microelectrophoretic 
techniques such as capillary electrophoresis (CE).5 While these measurements are highly 
sensitive, quantitative, and possess great multiplexing potential, a continuing bottleneck for 
ex vivo applications is the delivery of fluorescent reporters into the cell cytoplasm. To date, 
delivery of these reporters has relied on low throughput methods such as microinjection or 
cell-penetrating peptides (CPPs) which predominantly deliver cargo to endosomal 
compartments.6 Overcoming these limitations would be beneficial particularly when assaying 
clinical samples. Delivering a reporter en masse into the cytosol of a population of cells 
would dramatically improve overall throughput when coupled to an automated analysis 
system, enabling sampling from sufficient numbers of cells for statistical analyses and 
inference of aberrant phenotypes.  
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We aimed to address such challenges through chemical and instrumentation 
innovations. Specifically, we have developed a cell permeable, photoactivatable (i.e. 
“caged”) reporter which is masked as a substrate until UV light induces a photochemical 
conversion of the molecule into its substrate form (Figure 3.1). When the programmable 
reaction time of the caged reporter is paired with automated single cell-CE, significantly 
higher throughput measurements of kinase activity from single cells are achieved, which has 
the potential to circumvent current technological gaps in biosensor development.  
3.3 Materials and Methods 
3.3.1 Materials 
O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate(HCTU), 6-carboxyfluorescein (6FAM), Fmoc-protected amino acids, 
and NovaSyn TGR resin were purchased from Chempep and NovaBiochem. Purified 
recombinant Akt was purchased from EMD Millipore (14-276). PANC-1 cells were supplied 
from ATCC. All other reagents and solvents were purchased from Sigma-Aldrich or Fisher.  
3.3.2 Peptide Synthesis 
 Peptides described in this chapter were synthesized by Dr. Qunzhao Wang in the 
laboratory of Professor David Lawrence.  
3.2.2.1 Synthesis of Caged Threonine: N-(9-Fluorenylmethyloxycarbonyl)-O-(4,5-
dimethoxy-2-nitrobenzyl)-L-threonine (Fmoc-Thr(O-(4,5-dimethoxy-2-nitrobenzyl))-
OH)  
 
Triflic anhydride (18 µL, 0.2 mmol) in 1 mL anhydrous methylene chloride was 
added slowly to a solution of N-(9-Fluorenylmethyloxycarbonyl)-L-threonine allyl ester 
(Figure 3.2, S1a) (1.3 g, 3.4 mmol, prepared following reported method7 from Fmoc-Thr-
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OH) and 4,5-dimethoxy-2-nitrobenzyl trichloroacetimidate (1.2 g, 3.4 mmol, prepared 
following reported method6 in 40 mL anhydrous methylene chloride kept under nitrogen at 
room temperature.8 The resulting dark green solution was stirred overnight in the dark. The 
resulting solution was filtered, concentrated, dissolved in small amount of methylene 
chloride and run through a 50 g silica column with 30-40% ethyl acetate in hexane. The 
desired fraction was collected, concentrated (0.89 g) and treated with Pd(PPh3)4 (1.7 g, 1.5 
mmol) in 40 mL chloroform containing 1 mL acetic acid and 4 mL N-methylmorphorline for 
4 h. The reaction was treated with 0.1 N HCl until pH around 3-4, and extracted with ethyl 
acetate, dried (Na2SO4), concentrated, and purified on silica gel column (0-3% methanol in 
methylene chloride) to yield S1c (Figure 3.2) (210 mg, 12% yield in two steps). 1H NMR 
(400 MHz, CHLOROFORM-d) δ ppm 1.36 (d, J=6.27 Hz, 3 H) 3.93 (s, 3 H) 3.95 (s, 3 H) 
4.26 (t, J=7.03 Hz, 1 H) 4.30-4.38 (m, 1 H) 4.48 (d, J=6.78 Hz, 1 H) 4.55 (dd, J=9.29, 2.51 
Hz, 1 H) 4.86 (AB quartet, ∆ δ =0.28, J=14.56 Hz, 2 H) 5.55 (d, J=9.79 Hz, 1 H) 7.11 (s, 1 
H) 7.28 (s, 1 H) 7.32 (t, J=7.40 Hz, 2 H) 7.42 (t, J=7.40 Hz, 2 H) 7.57 - 7.67 (m, 3 H) 7.78 
(d, J=7.53 Hz, 2 H). ESI MS calculated for C28H28N2O9 + H
+ (M+) m/z: 537.2, found 537.2.  
3.2.2.2 Synthesis of Caged Threonine-Containing Peptide 1: 6FAM-Gly-Arg-Pro-
MeArg-Ala-Phe-Thr(O-(4,5-dimethoxy-2-nitrobenzyl))-Phe-MeAla-amide 
Coupling was achieved with two 5-min incubations in dimethylformamide (DMF) 
with 5 equivalents (eq) Fmoc amino acid, 5 eq HCTU, and 10 eq N,N-Diisopropylethylamine 
(DIPEA). Fmoc-Thr(O-(4,5-dimethoxy-2-nitrobenzyl)), Fmoc-MeArg(Pbf)-OH, Fmoc-
MeAla-OH and other regular protected amino acids were used. Fmoc deprotection was 
performed with two 2.5-min incubations with 20% piperidine in DMF. For couplings of 
aminos next to N-methylated amino acid (Attaching Phe to MeAla and attaching Pro to 
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MeArg), HATU in place of HCTU was used and the coupling was repeated for three times of 
1 h, then Capped with acetic anhydride. The N-terminus of all peptides was reacted with 5 eq 
6FAM, 5 eq diisopropylcarbodiimide (DIC), and 5 eq Oxyma in DMF overnight, and then 
treated with 20% piperidine in DMF for 30 min. The peptide was cleaved with trifluoroacetic 
acid: water: triisopropylsilane (TFA: H2O: TIS) in a ratio of 95 : 2.5 : 2.5, and purified by 
HPLC using H2O/Acetonitrile containing 0.1% TFA solvent system. C79H95N17O20, exact 
mass calculated 1601.7 (M), found (ESI+, m/z) 535.4 (M+3H+), 802.5 (M+2H+). 
3.2.2.3 Synthesis of Fmoc-L-serine allyl ester (S2a) 
150 mL water containing N-Fmoc-L-Serine (10.22 g, 31.2 mmol) and NaHCO3 
(14.36 g, 31.8 mmol) were combined with 60 mL CH2Cl2 containing 
tricaprylmethylammonium chloride (~11g) and allyl bromide (16 mL, 184.89 mmol), and the 
suspension was vigorously stirred at room temperature for 24 h. Water (300 mL) was added 
to the reaction mixture, and the suspension was extracted with methylene chloride (3 x 200 
mL). The combined organics were dried (Na2SO4) and the solvent was removed under 
reduced pressure. The crude residue was purified by silica flash chromatography (65:35 
hexanes:ethyl acetate) to yield S2a (Figure 3.3) as a white solid: 1H NMR (400MHz, CDCl3) 
 = 7.77 (d, J = 7.3 Hz, 2 H), 7.62 (br.d., J = 4.6 Hz, 2 H), 7.41 (t, J = 7.5 Hz, 2 H), 7.32 (t, J 
= 7.5 Hz, 2 H), 5.92 (tdd, J = 5.6, 11.0, 16.9 Hz, 1 H), 5.84 (d, J = 7.8 Hz, 1 H), 5.35 (d, J = 
17.1 Hz, 1 H), 5.27 (dd, J = 1.1, 10.4 Hz, 1 H), 4.69 (d, J = 5.4 Hz, 2 H), 4.53 - 4.46 (m, 1 
H), 4.46 - 4.37 (m, 2 H), 4.23 (t, J = 7.0 Hz, 1 H), 4.04 (dd, J = 3.1, 11.1 Hz, 1 H), 3.94 (dd, J 
= 2.9, 11.2 Hz, 1 H), 2.37 (br. s., 1 H). Exact mass calculated for C21H21NO5 367.14; found 
(ESI+) 368.1 (M + H)+, 390.1 (M + Na)+. 
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3.2.2.4 Synthesis of 4,5-dimethoxy-2-nitrobenzyl trichloroacetimidate (S2b) 
4,5-dimethoxy-2-nitrobenzyl alcohol (8.97 g, 42.08 mmol) and anhydrous K2CO3 
(14.2 g, 102.74 mmol) were stirred in 120 mL of anhydrous methylene chloride under 
nitrogen atmosphere. To the above mixture, trichloroacetonitrile (10 mL, 99.73 mmol) and 
anhydrous triethylamine (6 mL, 43.01 mmol mmol) were added and the reaction mixture 
stirred at room temperature for 24 h. Methylene chloride (300 mL) was added to the reaction 
mixture. Organic layer was collected and washed with 0.5 N HCl followed by solvent 
removal. The dried crude residue was purified by silica flash chromatography (75:25 
hexanes:ethyl acetate) to yield S2b (Figure 3.3): 1H NMR (400MHz, CDCl3)  = 8.51 (s, 1 
H), 7.75 (s, 1 H), 7.23 (s, 1 H), 5.78 (s, 2 H), 3.97 (s, 3 H), 3.96 (s, 3 H). Exact mass 
calculated for C11H11Cl3N2O5 355.97; found (ESI+) 374.9 (M + H3O)
+. 
3.2.2.5 Synthesis of N-(9-fluorenylmethyloxycarbonyl)-o-(4,5-dimethoxy-2-nitrobenzyl)-
L-serine allyl ester (S2c) 
Fmoc-serine allyl ester (1.74 g, 4.75 mmol) and the 4,5-dimethoxy-2-nitrobenzyl 
trichloroacetimidate (3.22 g, 9.04 mmol) were dissolved in methylene chloride (40 mL) and 
mixed under nitrogen atmosphere at room temperature. To the above solution was slowly 
added solution of triflic acid in methylene chloride (75 uL triflic in 5 mL methylene 
chloride). The reaction mixture was stirred at room temperature for 30 min after the 
completion of the triflic acid addition. N,N-Diisopropylethylamine (150 uL) in methylene 
chloride (10 mL) and silica gel were added to the reaction mixture and then concentrated 
under reduced pressure. The crude residue, adsorbed on silica, was purified by silica flash 
chromatography (67:33 hexanes:ethyl acetate) to afford S2c (Figure 3.3) : 1H NMR 
(400MHz, CDCl3)  = 7.77 (d, J = 7.5 Hz, 2 H), 7.72 (s, 1 H), 7.61 (t, J = 6.7 Hz, 2 H), 7.41 
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(t, J = 7.3 Hz, 2 H), 7.31(t, J = 6.6 Hz, 2 H), 7.18 (s, 1 H), 5.97 - 5.82 (m, 1 H), 5.71 (d, J = 
8.4 Hz, 1 H), 5.33 (d, J = 17.1 Hz, 1 H), 5.23 (d, J = 10.4 Hz, 1 H), 4.98, 4.92 (ABq, JAB = 
15.4 Hz, 2 H), 4.71 (d, J = 5.1 Hz, 2 H), 4.68 - 4.62 (m, 1 H), 4.48, 4.39 (ABXqd, JAB = 10.5 
Hz, JAX = 6.8 Hz, JBX = 6.9 Hz, 2 H), 4.24 (t, J = 7.1 Hz, 1 H), 4.18 - 4.04 (m, 2 H), 3.96 (s, 3 
H), 3.95 (s, 3 H), 3.94 - 3.89 (m, 1 H). Exact mass calculated for C30H30N2O9 562.20; found 
(ESI+) 563.2 (M + H)+, 585.2 (M + Na)+. 
3.2.2.6 Synthesis of N-(9-Fluorenylmethyloxycarbonyl)-O-(4,5-dimethoxy-2-
nitrobenzyl)-L-serine (S2d) 
The caged serine allyl ester (1.00 g, 1.78 mmol) was dissolved in chloroform (40 mL) 
containing acetic acid (21 mL) and n-methylmorpholine (3 mL). To the above solution was 
added Pd(Ph3P)4 (0.97 g, 0.84 mmol). The reaction mixture was stirred for 4 h at room 
temperature and neutralized by the addition of 0.1 N HCl till pH 4. The suspension was 
extracted by CH2Cl2 (x 2) and ethyl acetate (x 3). The organic extracts were dried (Na2SO4), 
and concentrated under reduced pressure. The crude residue was purified by silica flash 
chromatography (methylene chloride and then 48:2 methylene chloride:methanol) to yield 
S2d: 1H NMR (400MHz,CDCl3)  = 7.76 (d, J = 7.6 Hz, 2 H), 7.66 (s, 1 H), 7.60 (t, J = 5.9 
Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.31 (dt, J = 1.2, 6.4 Hz, 2 H), 7.10 (s, 1 H), 5.69 (d, J = 
8.3 Hz, 1 H), 4.97, 4.87 (ABq, JAB = 15.29, 2 H), 4.68 (br.s., 1 H), 4.53 - 4.37 (m, 2 H), 4.23 
(t, J = 6.7 Hz, 1 H), 4.12 (d, J = 9.2 Hz, 1 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 - 3.83 (m, 1 
H). Exact mass calculated for C27H26N2O9 522.16; found (ESI+) 523.2 (M + H)
+, 545.1 (M + 
Na)+. 
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3.3.3 Peptide Characterization Protocols 
3.3.3.1 In vitro Photoactivation Studies 
Benchtop photolysis was performed using a Nikon TE300 inverted microscope 
equipped with a Nikon 75W Xenon arc and an ultraviolet excitation filter (Nikon UV-2E/C) 
delivering a bandwidth of 360 ± 20 nm to the sample. 40 µL samples were contained within 
O-rings glued to No. 1 glass coverslips (Fisherbrand: 12-544-F) using polydimethylsiloxane 
(PDMS). UV power was measured with a ultra-violet radiometer (VWR, Radnor, PA). UV 
attenuation by the borosilicate glass coverslip was minimal, but accounted for by obtaining 
measurements with an identical glass coverslip in place between the light source and sensor. 
Varying light intensities were attained by placing Nikon neutral density filters between the 
sample and light source. Samples were exposed to UV light for up to 10 min, collected and 
stored in the dark, and diluted 20X before analysis with capillary electrophoresis with laser-
induced fluorescence (CE-LIF) detection. 
3.3.3.2 In Vitro Kinase Assay 
To ensure that the photoactivated peptide 2 possessed similar phosphorylation 
kinetics to that of the native substrate (NS), which had never been caged with DMNB, both 
were subjected to an in vitro phosphorylation assay using recombinant Aktα. Fully caged 
peptide 1 was also included in the assay to determine if it might be phosphorylated by the 
kinase. Following benchtop photolysis, photoactivated reporter 2 (15 µM) was mixed with 
recombinant Aktα (5.6 nM) in 8 mM MOPS (pH 7.0) with 4 mM MgCl2 and 1 mM ATP. 
Fully caged reporter 1 and NS peptide were separately incubated with Aktα under identical 
conditions. In negative control experiments, ATP was omitted from the reaction mixture. 
Assays were performed at 30 °C. After the addition of ATP to start the reaction, 6 µL 
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aliquots were removed at various times and the enzymatic reactions terminated by rapidly 
heating to 90°C for 4 min. Samples were then diluted 20x and analyzed by CE-LIF. 
 3.3.3.3 Enzymatic Generation of Peptide 3 (Phosphorylated Reporter) 
Standards of phosphorylated reporter 3 were enzymatically generated by incubating 
30 µM of peptide 2 with 6 nM recombinant Aktα, 2 mM ATP in 8 mM MOPS (pH 7.0) with 
4 mM MgCl2. Assays were incubated at 30 °C for 5 h. The molecular mass of 
phosphorylated peptide was confirmed by MALDI-MS with an AB SCIEX 4800 Plus 
instrument equipped with a 337 nm laser.  
3.3.3.4 Cell Culture 
PANC-1 cells were obtained from the American Type Culture Collection and 
maintained in a humidified environment atmosphere with 5% CO2 at 37 °C. The purity of the 
cell line was authenticated by the Human Cell Line Authentication (CLA) Analysis Facility 
at Duke University. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), streptomycin (100 µg mL-1), and 
penicillin (100 units mL-1).  
3.3.3.5 Lysate Phosphorylation Assay 
PANC-1 lysates were prepared in the presence of phosphatase and protease inhibitors. 
Cells were detached from the tissue culture surface with 0.5% trypsin and the reaction 
stopped by addition of DMEM containing FBS, and the cells were pelleted by centrifugation. 
The pellet was washed twice in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and the cells brought to a pellet by centrifugation. 
Lysates were prepared by resuspending the cell pellet in 400 µL lysis buffer and rapidly 
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freezing and thawing the pellet in liquid nitrogen for three cycles. Lysis buffer was 
comprised of 50 mM MOPS, pH 7.6, 200 mM NaCl, 4 mM pervanadate, 100 mM 
glycerophosphate, 12 mM sodium pyrophosphate, 40 mM NaF, 2 mM EDTA, 2 mM EGTA, 
4 µg/mL aprotinin, 4 µg/mL leupeptin, 2% Triton X-100, 20% glycerol, and 2 mM DTT. The 
protein content of cell lysates was 3.0 mg/mL. Protein concentration was determined by 
reaction with fluorescamine and bovine serum albumin was used to generate a calibration 
curve. 
3.3.3.6 Loading Cells with Caged Peptide 1 
PANC-1 cells were removed from tissue culture flasks with 0.5% trypsin. Cells (106) 
were incubated with Peptide 1 (10 µM, 10 µL) at the temperature indicated for 10 min. The 
cell suspension was then washed once with 0.5% trypsin, 2X with extracellular buffer (ECB; 
135 mM NaCl, 5 mM KCl, 1mM MgCl2 1 mM CaCl2 and 10 mM HEPES, pH 7.4) before 
photoactivation, lysis, or single cell analysis. 
3.3.3.7 Confocal Microscopy 
Confocal images were obtained at 37°C on an Olympus FV1000 scanning confocal 
system. All imaging was performed with a 40X (N.A.:1.3) or 60x (N.A.: 1.4) objective using 
a 488 nm laser for illumination. Image J was employed for image analysis.9 
3.3.3.8 Cytotoxicity Assay 
A colorimetric WST-8 cytotoxicity assay (Dojindo, Inc.) was utilized to detect the 
activity of intracellular lactate dehydrogenase (LDH) from cells after incubation with peptide 
and exposure to UV illumination. An absence of LDH activity from cells is an indicator of 
cellular toxicity and cytolysis.10 PANC-1 cells were plated in 96-well plates and allowed to 
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adhere overnight. Cells were incubated with caged peptide 1 (0, 1, or 10 µM) at 4°C for 10 
min. Cells were rinsed 1X with 0.5% trypsin, 2X with ECB and exposed to 4.2 mW/cm2 UV 
light (360±20 nm) for 4 min and rinsed 2X with ECB. Negative-control wells with cells but 
without peptide or UV irradiation underwent the same wash steps. ECB was replaced with 
100 µL DMEM containing penicillin, streptomycin (100 units mL-1, respectively) and 10% 
FBS. The cells were returned to the incubator for 2 h. WST-8 (10 µL) reagent was added to 
each well and the plate returned to the incubator. At 6 h, absorption at 450 nm was measured 
The colorimetric agents were removed and replaced with the indicated DMEM formulation. 
Measurements were repeated at 36 h Multiple comparison of means via One-way ANOVA 
with post-hoc Tukey multiple comparison of means demonstrated that no groups were 
statistically different from one other. (p = 0.50, 6 h; p = 0.28, 36 h) 
3.3.3.9 UV-Induced DNA Damage Assessed by Cyclobutane-Dimer ELISA 
 Cyclobutane dimers (CBD) formed by adjacent pyrimidines in DNA are a common 
type of UV-induced DNA damage.11 The UV-Induced DNA Damage ELISA Kit (Cell 
Biolabs: STA-322) was utilized to assess the presence CBDs in PANC-1 cells exposed to UV 
light. Cells were plated overnight in tissue culture treated 96 well plates and exposed to 
varying UV power as indicated in the text. Cells were rinsed 2x with Dulbecco’s Phosphate 
Buffered Saline (DPBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 
0.9 mM CaCl2, 0.49 mM MgCl2). Cells were fixed with 75% MeOH, 25% acetic acid for 30 
min, and 70% EtOH for 30 min at 25 °C. Samples were denatured and washed according to 
the manufacturer's instructions. The samples were then incubated with anti-CPD antibody, 
followed by a horseradish peroxidase (HRP) conjugated secondary antibody. The reaction 
was terminated with the addition of acid, and the absorbance was measured at 450 nm. The 
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CPD content sample was determined by comparing with a standard curve that was prepared 
from predetermined CPD-DNA standards . Comparison of groups by one-way ANOVA 
indicated that at least one group was statistically different (*p ≤ 0.05), and post hoc analysis 
by Tukey’s multiple comparison analysis illustrated that the amount of CBD detected after a 
22 min exposure to UV irradiation was statistically different (*p≤ 0.05) from that detected at 
all other time points, including those used for single cell analysis (4 min exposure).  
3.3.3.10 Capillary Electrophoresis 
CE-LIF separations of caged and photoactivated peptide samples were performed on 
a commercial instrument (ProteomeLab PA 800) in 30-μM inner-diameter, fused silica 
capillaries (30 cm total length, 20 cm length from inlet to detection window). Sample 
injection was initiated by applying 0.5 psi for 5 s to the inlet of the capillary. Electrophoresis 
was performed at 333 V/cm in CE buffer (100 mM borate, 15 mM SDS, pH 11.4). Analytes 
were detected with a solid state laser (excitation at 488 nm, emission at 520 nm). The 
capillary was sequentially rinsed for 2 min at 20 psi with 1 M NaOH, H2O, and CE buffer 
prior to each separation. Photoactivated peptide (%) or phosphorylation (%) or was measured 
as the ratio of the peak areas of phosphorylated and total reporter. 
3.3.3.11 Single Cell Capillary Electrophoresis 
Cells were cultured in glass-bottomed chambers which were then placed on the stage 
of a customized single-cell CE system with LIF. Cells were incubated with 10 µM peptide 1 
and photoactivated at 4.2 mW/cm2 for 4 min while in the cell chamber. Cells were maintained 
at 37°C using a constant flow of warmed ECB throughout the time for single cell analysis. 
After peptide uncaging, cells were incubated for an additional 20 min followed by cell lysis 
with a focused pulse from a Nd:YAG laser. Simultaneously the cell contents were loaded 
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into an overlying capillary (30 µm) by electrokinetic injection (5 s at 79 V/cm). Separations 
were performed at 250 V/cm and fluorescence excited at 488 nm with emission collected at 
525 + 25 nm.  
To determine the identity of peptides formed as a result to photoactivation or 
incubation within a cell, peptide standards were loaded into the capillary following the 
contents of a cell previously loaded with peptide 1 and photoactivated. In order to achieve 
optimal resolution between peaks, standards of varying concentration were loaded. Peptides 
1 and 3: 100 nM, peptides 2, iii, viii, i: 50 nM, vi, iv/v, ii: 25 nM . A voltage was then 
applied across the capillary to initiate electrophoretic separation. These electropherograms 
were compared to electropherograms with no standard co-injected to determine if that 
peptide fragment was formed. To calibrate the amount of peptide on the electropherograms, a 
known concentration (as described above) of standard of each intact peptide was loaded into 
the capillary, electrophoresed, and the area under the peak calculated. Spontaneous fluid 
displacement was experimentally determined to contribute to 20.2% ((0.10 nL) of the total 
volume injected, bringing the total injection volume to 0.48±0.02 nL . Poiseuille’s equation 
was utilized to estimate the moles of peptide injected due to gravity and spontaneous fluid 
displacement. The moles of peptide injected for each standard were as follows: Peptides 1 
and 3: 4.77 x 10-20 mol, peptides 2, iii , viii, i: 2.385 x 10-20 mol, vi, iv/v, ii: 1.19 x 10-20 mol .  
3.3.3.12 Fabrication of Cell Traps 
Cell traps were fabricated from 1002F-50 negative photoresist as described 
previously.12 Coverslips were spin-coated (Laurell Model WS-650-23, Laurell Technologies) 
with 1002F-50 photoresist, and baked at 95°C for 55 min (Table 3.2). A chrome photomask 
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was placed over the photoresist-coated coverslip and exposed to UV light (650 mJ/cm2), 
crosslinking the exposed photoresist. The photoresist-coated coverslip was then developed 
using SU-8 developer for 3 min, rinsed with isopropanol, and sequentially hard baked. Well 
depth (44 ± 1 µm) was measured using a profilometer (KLA Tencor model P-15; San Jose, 
CA).  
3.3.3.13 Cell Trap Loading 
Prior to trapping cells within the microwells, photoresist traps were plasma cleaned 
(Harrick Plasma) for 10 min to promote wetting of the wells. Having observed a large 
distribution in the diameter of PANC-1 cells (15-40 µm), we also optimized the size the 
photoresist wells to enable trapping single cells of all sizes to prevent inadvertent 
subpopulation profiling. 20 µL caged peptide 1-loaded PANC-1 cells (1 million cells mL-1) 
were deposited directly over the traps and allowed to settle for 2 min. Excess cells were 
removed by rinsing with ECB buffer. The trapped PANC-1 cells were continuously bathed in 
ECB (37°C, flow rate of 1 mm s-1) for the duration of automated CE analysis. The entire 
array of cells were simultaneously photoactivated by exposure at 4.2 mW/cm2 for 4 min 
before transfer onto the automated capillary electrophoresis system. 
3.3.3.14 Automated Single-Cell Capillary Electrophoresis 
A glass-PDMS cassette housing the cell traps similar to that described previously was 
used for the automated, single-cell analysis by CE.13 A 3-D printed housing held the cassette, 
electrodes and buffer inlet/outlets securely on the stage of an automated, inverted microscope 
(Ti-E, Nikon, Melville, NY). Since the buffer utilized for separations of caged reporter had a 
low surface tension relative to that used previously, a 130 µM height difference was 
fabricated between the two liquid channel pieces to safeguard against CE buffers spilling into 
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the air gap and mixing, which would negatively affect cell viability. Cells were maintained at 
37 °C by the flowing buffer as well as a heated microscope stage insert. Customized software 
(Python, Wolfeboro Falls, NH and MicroManager, Vale Lab, UCSF) identified the address of 
each cell trap and moved the motorized stage as described previously.13 Each cell trap that 
did not contain a single cell was removed from the program’s list of well addresses to be 
interrogated, so that only wells with single-cells were analyzed. All other tasks were 
automated using LabVIEW (National Instruments, Austin, TX). 
During automated single-cell analysis, the following events occurred sequentially 
under computer control. The microscope stage moved to the address of the first cell to be 
analyzed, placing the cell directly below the inlet of a capillary. The capillary was aligned 35 
µm above the plane of the microwells. A focused laser pulse lysed the cell by creating a 
cavitation bubble and the cell’s contents were then electrokinetically loaded into the 
capillary. Electrokinetic injections were performed by the application of 8 kV across the 
capillary for 1 s. The voltage was then set to zero as the stage moved through the air channel 
to the center of the electrophoretic buffer channel. A voltage of 10 kV (0.25 kV cm-1) was 
applied across the capillary for 500 s to separate the cellular contents. The voltage was then 
set to zero for 1 s as the stage moved back to place the capillary at the address of the next cell 
to be assayed. The next cell was lysed, then injected, and this entire process was repeated 
until all of the cells in the array were analyzed. The capillary was interrogated 4 cm from the 
inlet end by the focused beam of a fiber-coupled diode-pumped solid-state 473 nm laser and 
the fluorescence of the analytes detected with a photomultiplier tube. The analytes were 
identified by comparison of their migration times to that of standards. The peak areas of 
known quantities (moles) of each above mentioned peptide were used to calculate the moles 
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of peptide contained in each cell. A brightfield image of each cell, taken immediately prior to 
the single-cell experiment, was used to measure cell diameter. 
3.4 Results and Discussion 
3.4.1 In vitro Characterization of Caged Peptide Reporter 1 
The native substrate (NS) Akt peptide reporter 6FAM-GRP-(MeR)-AFTF-(MeA)-
Amide (where MeR and MeA represent N-methylated versions of native amino acids) has 
favorable phosphorylation kinetics and demonstrated resistance to intracellular 
degradation.14,15 NS possesses a single hydroxyl group that when coupled to a 
photoremovable DMNB group should block phosphorylation by Akt and render the reporter 
inactive as a substrate. As demonstrated by Figure 3.4 and Figure 3.5 (A,B) the 
photochemical conversion of this caged reporter can be controlled by varying both 
illumination duration and intensity, enabling investigator-controlled activation of the reporter 
including tuning its concentration. Predictably, photolysis kinetics are attenuated in cell 
lysates due to the absorption of UV wavelengths by intracellular molecules. Importantly, 
uncaged reporter 2 is phosphorylated at a rate indistinguishable to that of NS, both in vitro 
and in cell lysates (Figure 3.5C). The caged version 1 was not phosphorylated and did not 
spontaneously uncage to a measureable degree during assays. 
3.4.2 Cell Loading of Caged Reporter 1  
Having demonstrated that 1 was photoactivated and phosphorylated by Akt, we 
explored the delivery options for this reporter. Since NS is excluded from PANC-1 cells, 
prior work required microinjection of the reporter into cells, a slow and difficult process. A 
variety of CPPs exist for intracellular peptide delivery, but these strategies often utilize 
endosomal pathways resulting in significant peptide degradation or entrapment in the 
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endosome with little to no delivery to the cytosol, the primary location of endogenous Akt.16-
18 These challenges were manifested in our initial attempts to render NS cell permeable, with 
multiple CPPs19,20 appended to the reporter resulting in punctate uptake indicative of an non-
cytoplasmic location (Figure 3.6). However, NS when caged with DMNB to generate 1 was 
sufficiently hydrophobic to enter into the cytosol when incubated with PANC-1 cells (Figure 
3.7, 3.8A). The uncaged peptide was not identified in cells after loading the caged peptide 
(n=12) indicating that entry into the cytosol did not result in cleavage of the protecting 
DMNB group (Figure 3.9). Additionally the diffuse (rather than punctate) appearance of the 
fluorescence after loading peptide into the cells (Figure 3.7) combined with the observed 
phosphorylation of the reporter (post photoactivation) (Figure 3.8D) suggested delivery into 
cytosol rather than a cytosolic subcompartment.  
Quantification of intracellular peptide by CE revealed a correlation (R2 = 0.79) 
between the total moles of fluorescent reporter (𝑛𝑡𝑜𝑡𝑎𝑙 =  𝑛𝑐𝑎𝑔𝑒𝑑 + 𝑛𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑟𝑦𝑙𝑎𝑡𝑒𝑑 +
𝑛𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑 ) and the cell diameter (Figure 3.8E). Interestingly, when NS was modified with a 
DMNB-caged serine moiety rather than threonine, it retained cell permeable properties 
(Figure 3.10), suggesting that the addition of DMNB may be competent to render peptides of 
similar hydrophobicity cell permeable. This is consistent with recent studies which generated 
an angiotensin II analogue which was capable of entering cells upon linkage with DMNB.21  
3.4.3 Monitoring Intracellular Akt Activity Utilizing Caged Reporter Peptide 1 
We next evaluated the ability of this reporter to sense Akt activation after photolysis 
within intact PANC-1 cells. Akt is upstream of DNA repair mechanisms and is known to be a 
stress-activated kinase. Consequently, it was important to understand whether the UV 
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exposure needed for uncaging itself might cause DNA damage or activate the enzyme. CE-
LIF analysis revealed that in intracellular photolysis experiments, 96±2.2% the reporter was 
uncaged when illuminated for 4 min with 4.2 mW cm-1 of UV light, an energy that did not 
induce cytotoxicity (Figure 3.11) or DNA pyrimidine lesions (Figure 3.12). Using these 
uncaging conditions, we assessed Akt activation and inhibition in single PANC-1 cells 
(Figure 3.8 D,F). After photolysis, the contents of single cells were assayed by CE and the 
phosphorylated sensor was quantified. Minimal Akt activity as indicated by very little 
peptide phosphorylation was detected in the absence of exogenous stimuli (Figure 3.8F), 
which agrees with prior reports utilizing NS and suggests that uncaging did not activate 
Akt.15 Pathway stimulation or inhibition in response to TNFα, or TNFα + LY294002 was 
then assayed We observed significant heterogeneity of reporter phosphorylation in response 
to TNFα stimulation (0-100%), which is consistent with ours and others’ observations of 
mosaic Akt activation across cell populations.22-24 Treatment with LY294002 blocked 
reporter phosphorylation in response to TNFα, as expected since PI3K is downstream of the 
TNF receptor. We were also capable of identifying all degradation products of the reporter 
(i-viii, nomenclature in Table 3.1) 
3.4.3 Improved Throughput of Kinase Activity Measurement with Caged Peptide 1 
Paired with an Automated Capillary Electrophoresis System 
Having produced a cell permeable and photoactivated Akt reporter, we next sought to 
harness these unique properties to enhance the rate of single-cell protein-kinase analysis. Our 
prior work utilizing microinjection of NS possessed a very limited throughput of 0.5 cell h-
1.14,15 We’ve recently reported an automated system that can quantify kinase activity as 
rapidly as 3.5 cells min-1, which rivals microfluidic separation systems while still offering 
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excellent (10-20 mol) detection limits.13,25 A limitation for this system, however, is that 
reporters are acted upon during the loading process into the cell so that the reaction time in 
the cell is unknown. These challenges are uniquely addressed by the Akt reporter 1, which is 
membrane permeant with a programmable reaction start time (uncaging).  
We conducted a pilot study utilizing the automated single-cell CE system in which all 
cells in a population were simultaneously photoactivated to assess Akt activity as a function 
of time. Prior to single cell experiments, the cell traps housing individual PANC-1 cells were 
optimized. Traps were fabricated according to the process parameters in Table 3.2 with a 
range of diameters, and it was found that plasma treatment for 10 min was optimal to wet 
wells, and that 45 µm diameter wells were most effective at trapping individual cells (Figure 
3.13). Cells were loaded with caged reporter 1, photoactivated, and serially analyzed (n 
=109) (Figure 3.14). Among the cells assayed, the photoactivation efficiency was 97±2.8%, 
and the amount of reporter loaded was 42.4±42.7 amol. The lack of correlation (R2 = 0.018, 
Figure 3.15) between the total peptide (amol) detected and the dwell time within an intact 
cell suggests that the reporter was not exported over the analysis period.  
An oft overlooked commonality among peptides and sensor proteins, even those 
engineered for stability, is their eventual degradation within the intracellular context. Since 
phosphorylation and degradation can have similar effects on sensor fluorescence, this is a 
particular challenge with many protein-based sensors using fluorescence-resonance energy 
transfer or lifetime imaging which rely on molecular proximity and/or fluorescence decay 
rate to readout probe phosphorylation.3,26 In contrast, the single-cell CE system measures 
intact and degraded reporter as well as that phosphorylated to accurately quantify 
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phosphorylation rate (Figure 3.14B). When peptide standards of known concentration are 
also paired with single-cell CE utilized, the moles of the different peptide species are readily 
quantified (Figure 3.14C,D). Rather than simply increasing as a function of reporter 
incubation time, we found that Akt reporter phosphorylation was highly heterogeneous at all 
times measured. This may suggest that the peptide phosphorylation reaches equilibrium 
between kinases and their opposing phosphatases, and the balance point is unique for each 
cell. Since the most frequent aberration resulting in elevated Akt activity in cancer is 
deactivation of the downstream phosphatases PTEN, the measurement of this equilibrium 
point is also a valuable snapshot of the entire signaling node.  
Measurement of peptide degradation provided insight into how peptides were 
modified over time within single cells (Figure 3.14D; fragment nomenclature in Table 3.1). 
For cells analyzed at 15±1 min (n=11) after reporter uncaging, both phosphorylated reporter 
3 and full length reporter 2 were present as well as the 8-,4-and 5-amino acid proteolysis 
products, viii and iv/v. At 29±1 min (n=14), cells contained 2 and significant amounts of 3, 
but with substantial quantities of peptide fragments iv/v. By 45±1 min (n=10) 3 and 2 
remained, but the dominant peptide forms were 5 amino acids or less. The formation of key 
fragments such as ii, iv/v, and viii indicate that the reporter is acted upon by peptidases 
targeting basic and hydrophobic amino acids such as arginine and phenylalanine, 
respectively.  
3.5 Conclusions 
The generation of a cell permeable, photoactivated reporter enabled analysis (7.2 cells 
h-1) of kinase activity in a population of cells; a considerable benefit considering similar 
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caged kinase reporters have required microinjection or transfection. Photoactivation of 
DMNB-caged peptide enabled investigator control of reporter concentration as well as 
programmable reaction times. The membrane-permeant qualities imparted by the DMNB 
group, which may be generalizable beyond the peptides tested here, are highly valuable in the 
development of peptide sensors, and enable measurement from sufficient cells for 
meaningful statistical analysis. Overall, throughput was improved 14.4-fold with this reporter 
and we expect that outfitting peptide sensors with DMNB will shine a light on the role of 
aberrant kinase activity in small samples of clinical interest.  
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3.6 Figures and Tables 
 
Figure 3.1 Schematic of Peptide Caging and Photoactivation.  Native substrate 
(NS) was chemically caged with DMNB to generate 1, which is delivered intracellularly. 
Photolysis releases the active sensor 2 which is phosphorylated (3) and measured in single 
cells by automated single-cell, capillary electrophoresis.  
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Figure 3.2 Synthesis of Fmoc-Thr(DMNB)-OH. 
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Figure 3.3 Synthesis of Fmoc-Ser(DMNB)-OH. 
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Figure 3.4 In Vitro Photoactivation of Caged Reporter 1. 10 µM peptide 1 was 
exposed to 360 ± 20 nm light at an intensity of 1.5 mW/cm2 for 0 (A), 2 (B) or 10 (C) min 
and the sample separated by CE-LIF. Peak labels correspond to the caged reporter 1 and the 
photoactivated (uncaged) reporter 2, respectively. 
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Figure 3.5 In Vitro Characterization of Caged Akt Reporter 1. A) Photolysis of 
10 µM 1 in extracellular buffer (ECB) and B) PANC-1 lysate at varying intensities. C) 
Phosphorylation assays with recombinant Akt. Closed symbols: in vitro assays, open 
symbols: experiments performed in PANC-1 lysates. 
101 
 
 
Figure 3.6 Loading Reporter Conjugated to Cell Penetrating Peptides 
(CPPs) into PANC-1 Cells. Shown are confocal fluorescence images of Xentry-peptide 
NS (A,B) and TP2-peptide NS (C,D) incubated with PANC-1 cells for 20 min at 37 °C (A,C) 
or 4°C (B,D). Xentry-peptide NS represents Ac-lclrpvg-Lys(6FAM)-GRP-MeR-AFTF-MeA 
while TP2-peptide NS denotes NH2-pliylrllrgqf-Cys-SS-Cys(NH-6FAM)-GRP-MeR-AFTF-
MeA-Amide. Lower case amino acid abbreviations indicate D-stereoisomer amino acids. 
Scale bar is 15 µm. 
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Figure 3.7 Loading of Caged Peptide 1 at Various Temperatures. Confocal 
images of PANC-1 cells after incubation with 10 µM peptide 1 for 10 min at a) 37°C, b) 
25°C c) 4 °C. The scale bar is 10 µm. 
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Figure 3.8 Intracellular Characterization of Peptide 1. Images of cells incubated 
at 4 °C with a) reporter 1, b) reporter 2 c), or without peptide d) Single-cell Akt activity 
measured by chemical cytometry with the electrophoretic peaks labeled as 1, 2, and 3 for 
caged, photoactivated, and phosphorylated reporter, respectively. 6FAM-labeled proteolytic 
products of 1 are marked as i-viii (Table 3.2). The trace labeled (STND) demonstrates the 
migration time of a standard solution of the peptides. e) The attomoles of reporter loaded as a 
function of cell diameter (R2 = 0.79). f) Akt activity for a population of single cells analyzed 
20-min post-photolysis. Prior to loading with 1, photolysis and analysis, cells were serum 
starved (labeled as basal) or pretreated with 100 nM TNFα or 10 µM LY294002. 
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Figure 3.9 Caged Peptide 1 Does Not Spontaneously Photoactivate in the 
Intracellular Environment. (A-D) PANC-1 cells were loaded with peptide 1, incubated 
for 20 min and analyzed by chemical cytometry. In all cases, no free peptide 2 was detected, 
indicating that DMNB is not liberated into the intracellular environment without UV 
illumination.  
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Figure 3.10 Loading of Caged Serine Reporter at Various Temperatures. 
Confocal fluorescence images of PANC-1 incubated with 10 µM caged serine peptide 
(6FAM-GRP-MeR-AF(DMNB-S)F-MeA-Amide) for 10 min at a) 37°C, b) 25°C c) 4 °C. 
The scale bar is 20 µm. 
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Figure 3.11 PANC-1 Cell Cytotoxicity Assessment After Loading with 
Peptide 1 Followed by Photoactivation. PANC-1 cells were incubated with peptide 1 
(0-10 µM) and then illuminated with 4.2 mW/cm2 of UV light for 0 min (solid bars) or 4 min 
(hashed bars). Lactate dehydrogenase (LDH) activity was measured as a metric of cell 
viability after a) 6 and b) 36 h. Multiple comparison of means via One-way ANOVA with 
post-hoc Tukey multiple comparison of means demonstrated that no groups were statistically 
different from one other. (p = 0.50, 6 h; p = 0.28, 36 h).  
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Figure 3.12 DNA Damage as a Result of UV Irradiation. PANC-1 cells were 
exposed to 360±20 nm at 4.2 mW/cm2 for 0-22 min. DNA damage was assessed by fixing 
cells and assaying for pyrimidine cyclobutane dimers. N=3. Comparison of groups by one-
way ANOVA indicated that at least one group was statistically different (*p ≤ 0.05), and post 
hoc analysis by Tukey’s multiple comparison analysis illustrated that the amount of CBD 
detected after a 22 min exposure to UV irradiation was statistically different (*p≤ 0.05) from 
that detected at all other time points.  
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Figure 3.13 Optimization of Cell Traps.  a) Effect of plasma cleaning on the time 
necessary to completely wet an array of photoresist cell traps with ECB. b) The percentage of 
wells trapping a single cell is depicted for various trap diameters. Multiple comparison of 
means via one-way ANOVA with post-hoc Tukey method analysis was utilized to evaluate 
statistical differences. (**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).  
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Figure 3.14 Automated single cell analysis.  a) Schematic of the microfabricated 
system used for automated CE analysis. Cell traps (45 µM deep, inset) were loaded with 
PANC-1 cells and the peptide within the cell was photoactivated. The cells were then 
assayed by automated single-cell CE. b) Separation of intracellular contents from 
consecutively analyzed cells. The inset depicts 11 cells (A-K), and the expanded region 
shows cells E-H. c) Caged reporter loading and metabolism in PANC-1 cells. Each colored 
data point represents a single cell with the color denoting the moles loaded into the cell. d) 
Reporter metabolism at various time points after photoactivation. Each overlay (color) 
represents the metabolism from a single cell.  
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Figure 3.15 Moles of Peptide Detected (𝑛𝑡𝑜𝑡𝑎𝑙 =  𝑛𝑐𝑎𝑔𝑒𝑑+ 𝑛𝑝ℎ𝑜𝑡𝑜𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒𝑑 +
 𝑛𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑟𝑦𝑙𝑎𝑡𝑒𝑑 +  𝑛𝑑𝑒𝑔𝑟𝑎𝑑𝑒𝑑) From Single Cells at Various Times After 
Photoactivation. The red line inidicates a linear fit of the data, suggesting there is minimal 
correlation between the peptide detected from the individual cells and the time after 
photoactivation.  
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Table 3.1 Proteolytic Fragments of Reporter 2 
Name Proteolytic Fragment 
i 6FAM-G-OH 
ii 6FAM-GR-OH 
iii 6FAM-GRP-OH 
iv 6FAM-GRP-R-OH 
v 6FAM-GRP-R-A-OH 
vi 6FAM-GRP-R-AF-OH 
vii 6FAM-GRP-R-AFT-OH 
viii 6FAM-GRP-R-AFTF-OH 
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Table 3.2 Process Parameters for Photolithography of Cell Traps 
Parameter Value 
Desired Depth 45 µm 
Spin Coating (1) 500 rpm ; 10 s 
Spin Coating (2) 2200 rpm; 30 s 
Softbake (95°C) 55 min 
UV Exposure (mJ/cm2) 650 
Develop 3 min 
Hardbake (1) 95°C 30 min 
Hardbake (2) 120 °C 15 min 
Hardbake (3) 150 °C 6 h 
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Chapter 4: Iterative Redesign of the Akt Kinase Substrate Reporter for Improved 
Proteolytic Resistance 
 
4.1. Peptide Stabilization Strategies 
Owing to their straightforward synthesis, shelf stability, and customizable properties, 
short peptides have found diverse employment in biomedical research, including their 
integration within in vitro assays. Peptide substrates are commonly incubated with purified 
kinases in library screens to assess the therapeutic promise of targeted inhibitors, identify 
substrate consensus sequences, or for development of peptides that are themselves 
inhibitors.1-3  However, these highly simplified environments often fail to recapitulate the 
complex intracellular interactions they were designed to model, which has resulted in the 
popularization of lysate and in-cell assays. These more accurately approximate the in vivo 
response, but many short peptides undergo rapid degradation at one or more sites once 
exposed to the cellular milieu, severely limiting their utility.4-7 Multiple strategies, described 
below, have been enacted to prevent proteolytic fragmentation and improve the lifetime of 
peptide sensors in lysates and individual cells.  
Modifications at either terminus are among the simplest to protect short sequences 
from peptidases and proteases which can sequentially remove residues or cleave at internal 
sites. N-terminal acetylation and C-terminal amidation or polyethylene-glycol modification 
(PEGylation) have met with success, but in many lysates or cells these peptides still have 
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half-lives on the order of minutes, precluding their use in time resolved studies.8,9 More 
sophisticated approaches involve introducing secondary structure to peptides which reduce 
degradation by preventing entry into the tunnel-like catalytic site of cytosolic proteases. For 
example, the addition of β-turn sequences to the N-terminus of peptides improved their half-
life by 40-fold in cytosolic lysates.10 Similarly, peptide stapling aims to reduce proteolysis by 
introducing one or more hydrocarbon braces near sites of degradation, constraining peptide 
conformation.11 Complete cyclization of sequences is another popular route to prevent 
peptide degradation by generating secondary structure, although a shared drawback of these 
techniques is the decreased substrate recognition that often occurs after inducing these 
structural changes.12,13 Furthermore, these syntheses are rarely straightforward and may 
require significant chromatographic purification.10  
An intermediate tactic to stabilize peptides against proteolysis is the introduction of 
amino acids which are less frequently recognized by intracellular proteases, including non-
native and D-enantiomer residues. The inclusion of non-native N-methylated amino acids 
into several peptides have significantly protected them from proteolytic degradation.14 
Energy calculations showed that N-methylated peptides were also more likely to deviate 
from planar configurations than their native counterparts, hinting that subtle conformation 
differences imparted by such residues can have broad consequences on biological 
activity.15,16 Standard solid phase peptide synthesis techniques can be utilized to introduce 
such amino acids into sequences, representing an effective manner of improving peptide 
lifetimes in cell-based assays with a relatively low expertise barrier. This chapter describes 
the development of a strategy to stabilize the peptide substrate reporter VI-B at key cleavage 
locations through the introduction of non-native amino acids. 
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4.2 Iterative Redesign of the Akt Kinase Substrate VI-B 
As discussed in Chapters 2 and 3 of this dissertation, the peptide VI-B (6FAM-GRP-
MeArg-AFTF-MeAla) acts as an Akt substrate within single cells, but is also degraded into 
several fluorescent fragments as a result of proteolysis. The primary cleavage site of VI-B is 
cell-line dependent, but a major fragment observed in individual cells from xenograft mice 
possessing human PDAC tumors occurred between phenylalanine and N-methyl alanine 
(MeAla), resulting in an eight amino acid fragment.17 In this chapter, a degradation-resistant 
peptide substrate reporter, 76D (6FAM-GRP-MeArg-AFTF-Aib), was developed through 
modification of VI-B at this cleavage site.  
In previous studies, a starting peptide based on the consensus sequence of Akt 
underwent iterative non-native amino acid replacement at identified cleavage sites, which 
resulted in VI-B.18 This reporter featured improved phosphorylation efficiency and 4.5-fold 
improvement of peptide half-life in a lysate compared to the initial peptide, and was utilized 
for single cell studies described in this thesis. When incubated in single PANC-1 cells (a cell 
line derived from human pancreatic adenocarcinoma), the major cleavage site of VI-B (38 ± 
10% of total peptide) was between phenylalanine and N-methyl alanine (MeAla). The 
peptide library described in this chapter evaluates peptides with modified amino acids in 
these two locations. Multiple non-native amino acids were included in the library at these 
amino acid locations to increase peptide stability. Library members were screened for time to 
50% phosphorylation (t50%P) and half-life in a lysate (t1/2). The lead peptide from the library 
was then microinjected into single cells with no measureable degradation of the reporter, 
although minimal phosphorylation was observed. Microinjection of the lead peptide’s 
phosphorylated analogue revealed rapid dephosphorylation, suggesting that measurement of 
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Akt activity with an improved degradation-resistant reporter will require reporter 
modification or more complete inhibition of protein serine/threonine phosphatases (PSPs).  
4.3 Experimental Section 
4.3.1 Materials 
  9-fluoroenylmethoxycarbonyl (Fmoc) amino acids, resins, 2-(6-chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), 1-
(mesitylene-2-sulfonyl)-3-nitro-1,2,4-trizaole (MSNT) were procured from Novabiochem or 
ChemPep. AnaSpec supplied 6-carboxyfluorescein (6FAM), N-Hydroxybenzotrizaole 
(HOBt), and Fmoc-Nα-Me-Arg(Mtr)-OH. Fmoc-α-MeAla-OH was purchased from 
Advanced ChemTech. Recombinant active human Aktα was purchased from Millipore. 
Dulbecco’s Modified Eagle Medium (DMEM), was procured from Cellgro; 0.25% trypsin 
and penicillin/streptomycin were obtained from Gibco; fetal bovine serum (FBS) was 
purchased from Atlanta Biologicals. Bovine serum albumin (BSA) was procured from 
Calbiochem. All other reagents were described in previous chapters or were purchased from 
Fisher or Sigma-Aldrich.  
4.3.2 Peptide Synthesis and Characterization 
 Peptides described in this chapter were synthesized by Dr. Qunzhao Wang in the 
laboratory of Dr. David Lawrence at UNC-CH. The purity of peptide products was assessed 
with high performance liquid chromatography – mass spectrometry (HPLC-MS) and further 
purified with HPLC if necessary. Peptides were lyophilized, resuspended in Tris buffer (pH 
7.5), aliquoted, and stored at -80 °C.  
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4.3.2.1 Synthesis of Full Length Peptides 
 Automated Fmoc peptide synthesis methodologies (Prelude Peptide Synthesizer, 
Protein Technologies, Tucson,AZ) were employed to prepare full length substrate peptides 
containing an amidated C-terminus. Couplings were performed during two 5-min incubations 
in dimethylformamide (DMF) with 5 equivalents (eq) Fmoc amino acid, 5 eq HCTU, and 10 
eq N,N-Diisopropylethylamine (DIPEA). Couplings of amino acids adjacent to N-methylated 
residues were performed with three 60-min incubations in N-Methyl-2-prrolidone (NMP) 
prior to capping with acetic anhydride. In some cases, coupling of amino acids required 
treatment with 5 eq of Fmoc amino acid, 5 eq HCTU, and 10 eq DIPEA in N-methyl-2-
pyrrolidone (NMP) for 3 h, repeated for a total of three iterations. Fmoc deprotection was 
conducted with two 2.5-min incubations with 20% piperidine in DMF. Fluorescent labeling 
was achieved at the N-terminus of all peptides by reacting 5 eq of 6FAM, 5 eq 
diisopropylcarbodiimide (DIC), and 5 eq HOBt in DMF overnight, with subsequent 
treatment with 30% piperidine in DMF for 30 min. Peptides were cleaved from the resin 
overnight in a solution of trifluoroacetic acid (TFA): Phenol : H2O : TIS in a ratio of 88:5: 
5:2. In all cases, cleaved peptides were precipitated with ether and dried under air. Purity was 
determined with HPLC-MS and further purified with HPLC if necessary.  
4.3.2.2 Synthesis of Peptide Fragments Possessing a Free Acid 
 Peptide fragment standards possessing a free carboxylic acid on the C-terminus were 
synthesized using either a 2-chlorotrityl or Wang resin. With the 2-chlorotrityl resin, 1 eq of 
the first Fmoc amino acid and 4 eq of DIPEA in dry CH2Cl2 was reacted with the resin for 2 
h in a dry glass vial on a shaker. When using the Wang resin, 10 eq of the first Fmoc amino 
acid in CH2Cl2 was incubated with 7.5 eq 1-methyl-imidzaole and 10 eq MSNT for 15 min in 
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a dry glass vial on a shaker. The subsequent amino acids were coupled as described above for 
the full-length, amidated peptides and each peptide was fluorescently labeled with 6FAM on 
the N-terminus as described above. 
4.3.2.3 Synthesis of a Myristoylated Peptide Reporter 
 Synthesis of a cell-penetrating 76D peptide reporter, termed Myr76D, involved the 
coupling of a carboxyfluorescein diacetate-linked 14-carbon fatty acid to the N-terminus of 
76D. After coupling the fluorophore to the peptide, it was treated with 30% piperidine and 
washed. Peptide was then incubated with 10 eq myristic acid, HCTU, Oxyma, and 20 eq of 
DIPEA for 3 h.  
4.3.3 In vitro Kinase Assays 
 Peptide phosphorylation assays were performed with 6 nM recombinant, purified 
human Aktα at 30 °C in assay buffer [8 mM MOPS (3-(N-morpholino)propanesulfonic acid), 
pH 7.0, 0.2 mM EDTA, 4 mM MgCl2, 1 mM ATP] with 25 µM peptide substrate. Aliquots 
were removed over time from the reaction mixture and quenched by incubation at 90 °C for 4 
min. Samples were then subjected to capillary electrophoresis with laser induced 
fluorescence detection (CE-LIF), and the amount of peptide phosphorylation was determined 
by dividing the peak area of phosphorylated peptide versus all other peaks in the 
electropherogram.  
4.3.4 Measurement of Kinetic Parameters by Fluorescence Anisotropy 
 Kinase assays were performed as described above, except that the substrate 
concentration was varied from 0-200 µM. Initial estimates of assay timepoints required to 
generate small amounts (<10%) of phosphorylated peptide were performed by separating 
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samples with CE-LIF. Once timepoints were optimized, the immobilized metal ion affinity-
based fluorescent polarization (IMAP) assay (Molecular Devices Corp., Sunnyvale, CA) was 
employed to detect phosphorylated peptide in each reaction mixture. Briefly, this assay 
employs the high-affinity interaction of trivalent metal nanoparticles with phosphoryl groups 
to detect phosphorylated peptides. A calibration curve was generated by measuring the 
fluorescence anisotropy of standard mixtures of containing native and phosphorylated 
sequences. Recombinant Aktα was reacted with peptides to generate a sample of 100% 
phosphorylated peptide, and was confirmed by CE-LIF and Matrix Assisted Laser 
Desorption Ionization Mass Spectrometry (MALDI-MS). A florescence plate reader 
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) with an excitation of 485 nm (9 nm 
bandwidth) and emission of 525 nm (15 nm bandwidth) was employed to measure 
anisotropy. Assay samples were diluted to 100 nM for anisotropy measurements.  
4.3.5 Cell Culture 
PANC-1 cells, originating from a 56 year old male with Pancreatic Ductal 
Adenocarcinoma (PDAC) with metastases in the lymph node, were obtained from the 
American Type Culture Collection (Manassas, Virginia). This adherent cell line was cultured 
in DMEM medium supplemented with 10% FBS, streptomycin (100 µg/mL), and penicillin 
(100 units/mL) and was maintained in a humidified atmosphere at 37 °C with 5% CO2. Cells 
were cultured to a maximum density of 80% confluency and were disadhered from the 
growth surface into fresh media by treatment with 0.25% trypsin for 5 min.  
4.3.6 Peptide Degradation in Cell Lysates 
 PANC-1 cells were released from the growth surface with 0.25% trypsin treatment, 
pelleted via centrifugation, and washed 3X with Phosphate Buffered Saline (PBS; 137 mM 
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NaCl, 10 mM Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4) to remove excess growth 
media. Cell pellets were submerged in liquid nitrogen for 1 minute intervals with full 
thawing between each cycle at 37 °C, for a total of 3 cycles. The solution was then 
centrifuged at 14,000 x g for 15 min at 4 °C. The supernatant was collected and transferred to 
a sterile container where it was sustained at 4 °C until the point of the assay. The total protein 
content within the supernatant was determined with fluorescamine.19 A standard curve was 
generated by reacting various amounts of BSA (0 – 100 µg mL-1) with fluorescamine. 
Briefly, 30 µL of cell lysate was mixed with 10 µL fluorescamine (3 mg/mL in acetone) and 
incubated for 5 min at 25 °C in darkness. A fluorescence plate reader (SpectraMax M5, 
Molecular Devices, Sunnyvale, CA) with an excitation of 390 ± 4.5 nm and emission of 475 
nm (bandwidth 15 nm) was employed to measure the resulting fluorescence. Lysates were 
prepared to 3 mg mL-1 total protein in PBS immediately prior to use in degradation assays. 
Peptide lifetimes within cytosolic cell lysates were evaluated by mixing peptide substrate (1 
µM) with the prepared lysate and incubating the solution at 37 °C. Aliquots were removed 
over time and quenched by the addition of HCl to a final concentration of 100 mM. To obtain 
a 0 min timepoint, the lysate was pre-quenched with acid prior to the addition of peptide. 
Samples from these reactions were separated and detected with CE-LIF. Peptide fragments 
were identified by the addition of fragment standards (200 nM) to the acid-terminated 
aliquots, and comparing the electropherograms before and after the addition of the standard. 
Positive identification of a fragment was defined by a 50% increase (at minimum) of 
corrected peak area of the comigrating peak appearing in the degradation assay. Peptide 
lifetime, or the total amount of full-length peptide remaining in assay samples, was 
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calculated by dividing the peak area of the parent peptide by the total area of peaks in the 
electropherogram.  
4.3.7 Capillary Electrophoresis  
Separation of peptide samples were performed on a commercial CE-LIF instrument 
(ProteomeLab PA 800) in 50 μM inner diameter fused silica capillaries (30 cm length, 20 cm 
effective length). Sample injection was initiated by applying 0.5 psi for 5 s to the inlet of the 
capillary. Electrophoresis was performed at 333 V/cm in buffer. 100 mM borate, pH 7.7 was 
employed for CE separations of native and phosphorylated 59C. 100 mM Borate, 7 mM SDS 
at pH 9.5 was used in separations for all remaining peptide samples. Analytes were detected 
with an argon-ion laser (emission at 488 nm, detection at 520 nm). The capillary was rinsed 
for 2 minutes at 20 psi with 1 M NaOH, H2O, and sample buffer prior to each separation. 
Phosphorylation (%) or intact peptide (%) was measured as a ratio of integrated peak areas 
between modified and total reporter. 
4.3.8 Single Cell Capillary Electrophoresis 
 Single PANC-1 cells were analyzed by single cell CE-LIF as described in previous 
chapters, except that cells were either microinjected with VI-B, 76D, or phosphorylated 76D, 
and separations occurred in 400 mM Borate, pH 9.5.  
4.4 Results and Discussion 
4.4.1 Characterization of Peptides Following Replacement of C-terminal Phenylalanine 
 Starting with the C-terminal phenylalanine, amino acids on both the N- and C-
terminal side of the primary proteolysis clip site of VI-B were replaced with non-native 
residue analogs to determine if greater peptide stability could be gleaned. D-phenylalanine 
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and N-methyl phenylalanine (Figure 4.1A) were included in the sequence, both of which 
have been shown to impart stability to peptides.20,21 Peptides 59D and 59F (Table 4.1) were 
synthesized, purified, and incubated in a PANC-1 cytosolic lysate. Samples removed over 
time were separated by CE-LIF and the amount and number of fluorescent fragments 
determined. The peptides showed disparate resistance to degradation: 59D and 59F degraded 
into 5 and 3 fragments, respectively. To compare the two peptides, the percentage of intact 
peptide was plotted as a function of time, and the peptide half-life (t1/2) calculated. Peptide 
59D possessing N-methyl phenylalanine had a half-life of 43 ± 7.8 min, an approximately 2-
fold slower rate of degradation than the starting peptide. Conversely, peptide 59F containing 
D-Phenylalanine had a half-life of 142 ± 8.4 min, a 7.5-fold improvement in degradation 
resistance.  
 To assess whether these modified peptides, both of which possessed improved 
degradation resistance, retained their ability to act as substrates for Akt, each was incubated 
with recombinant, purified Akt in vitro, and phosphorylation over time was assessed by CE-
LIF. 59D failed to be phosphorylated by Akt after 120 min incubation, while 59F possessed a 
time to 50% phosphorylation (t50%P) of 126 ± 5.7 min, a rate over two-fold slower than the 
starting peptide (Figure 4.3). The inadequate phosphorylation of these peptides led to 
assessment of other non-native amino acid-based modifications. 
4.4.2 Characterization of Peptides Following Substitution of C-terminal N-Methyl 
Alanine 
 After determining that modifications at the 7th residue of VI-B resulted in improved 
degradation resistance, but at the sacrifice of phosphorylation efficiency, substitutions on the 
C-terminal side of the susceptible bond were explored. Peptides 76D, 59A, and 59C (Table 
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4.1) were synthesized with α-aminoisobutyric acid, N-methyl- α-aminoisobutyric acid, and 
N-benzyl alanine (Figure 4.1B), respectively. Peptides were then individually incubated in 
cytosolic PANC-1 lysates and degradation patterns monitored with CE-LIF. VI-B, 59A, and 
59C were metabolized into four fluorescent fragments, while 76D resulted in two 
fragmentation products (Figure 4.3). When each modified peptide was compared to the 
starting peptide, it was apparent that 76D was highly degradation resistant, with 92 ± 3.8% 
parent peptide remaining intact after 60 min. The half-life of this peptide in a lysate was 352 
± 5.2 min, an 18.5-fold improvement in degradation resistance over VI-B. Comparatively, 
peptides 59A and 59C possessed half-lives of 48 ± 13.8 and 20 ± 12 min, respectively.  
 The ability of each substituted peptide to undergo phosphorylation by Akt kinase was 
assessed via an in vitro assay. Peptides were incubated with recombinant, active Akt and 
samples taken over time were separated by CE-LIF. Peptides 59A and 59C were minimally 
phosphorylated, with t50%P values of 256 ±7.2 and 167 ± 7.8 min, respectively. This result, 
combined with rapid peptide degradation in lysates, precluded further study of these peptides. 
However, peptide 76D possessed a t50%P of 40 ± 10.3 min, a 1.4-fold improvement in 
phosphorylation rate from the starting peptide. Indeed, 76D both acted as an efficient 
substrate while resisting intracellular degradation to a high degree, and was determined to be 
the lead peptide from this library screen 
In order to quantitatively assess the ability of Akt to phosphorylate the lead peptide, 
76D, versus the starting peptide, VI-B, the kinetic parameters of KM and kcat were determined 
for each peptide. The amount of phosphorylated substrate was measured using the 
immobilized metal affinity fluorescence polarization (IMAP) assay, which employs the high-
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affinity interaction of trivalent metal nanoparticles with phosphoryl groups. 76D 
demonstrated a 4-fold lower KM than VI-B (15 µM versus 56 µM) as well as a 6.7-fold 
greater kcat (400 s
-1 versus 60 s-1). The ratio kcat /Km, known as the specificity constant, is a 
useful index for comparing the relative rates of substrate phosphorylation by Akt. 76D 
demonstrated a 25-fold greater kcat /Km ratio than VI-B (2.7 x 10
7 M-1 s-1 versus 1.1 x 106 M-1 
s-1), confirming its improved suitability as a degradation-resistant Akt substrate.  
4.4.3 Separation and Identification of Peptide Fragments 
 Although it was shown that the lead peptide 76D was resistant to degradation within a 
cytosolic lysate, it has been shown that peptide fragmentation patterns and rates can differ 
within an intact intracellular environment. 18,22 In order to identify the exact cleavage sites of 
any fragments occurring within individual cells as well as unambiguously identify 
phosphorylated and parent peptide in separations, standards consisting of all fluorescent 
fragments of the lead peptide (76D) were synthesized and characterized by CE-LIF. Under 
optimized conditions (400 mM Borate pH 9.5), full length peptide and phosphorylated 
peptide migrated at discrete times as single peaks (Figure 6.5), and fragments were 
identifiable by migration time. Thus, any fragments formed during single-cell incubations 
could be easily identified.  
4.4.4 Myr76D as a Cell Permeable Akt Reporter 
Studies of single intact cells with peptides such as 76D require loading of cells. This 
poses a large obstacle due to the selective permeability of cell membranes. Hydrophobic 
molecules such as steroids are lipid soluble and can diffuse through the phospholipid 
membrane, gaining entry into cells,23 while peptides generally cannot permeate the 
membrane owing to their bulk and charge. There are multiple methods for introducing 
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macromolecules into living cells. Microinjection has the highest delivery to toxicity ratio but 
is low throughput. Pinocytic loading, electroporation, and optoporation have also been 
utilized to introduce peptides into cells.24-27 While these methods are effectual for peptide 
loading, they are still capable of inducing significant cellular stress that may activate the Akt 
pathway, obscuring accurate measurements of normal versus aberrant enzyme activity. For 
this reason, a non-disruptive loading technique was attempted to translocate 76D into the 
cytosol. The addition of a C14 myristoyl chain to a peptide has been shown to promote 
passive entry of peptides into cells, with minimal endosomal uptake.26 However, in order for 
the reporter to be liberated from the membrane and diffuse into the cytosol where active Akt 
is located, the myristate moiety must be freed from the fluorescent peptide. A novel approach 
is illustrated in Figure 4.5 with 6-FAM replaced by a 6-carboxyfluorescein diacetate (6-
FAMDA) fluorophore, which is cleaved by intracellular esterases to its fluorescent anion.28 
The myristate group was coupled to one of the cleavable acetate groups, resulting in a 
detachable reporter.  
PANC-1 cells were incubated with Myr76D and visualized with fluorescence 
microscopy. No visible increase in fluorescence was detected compared to untreated PANC-1 
cells, suggesting minimal loading of the peptide, limited esterase cleavage, or possibly both. 
Loaded cells were subjected to single-cell lysis and separation by CE-LIF to assess the 
presence of any reporter phosphorylation, which would strongly suggest the reporter crossing 
the cell membrane and detaching from its hydrophobic tether. However, phosphorylation of 
Myr76D could not be confirmed due to extremely low signal from the cells. Notably, the 
same separation conditions were conducive to separation of myristoylated reporter as native 
peptide, and the myristoylated reporter possessed the same degradation resistant 
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characteristics as native 76D, with 93 ± 3.9% peptide remaining intact after 60 min in a 
PANC-1 lysate. Unfortunately, the limited loading of the reporter into cells precluded any 
future study with this peptide and this approach was ultimately abandoned. However, given 
the chemical innovations detailed in Chapter Three, it is possible that this peptide sequence 
could be rendered cell permeable through coupling with the hydrophobic caging group, 
DMNB.  
4.4.5 Kinase Activity Measurement in Single PANC-1 Cells 
 Evaluation of kinase activity at the single cell level permits the observation of 
signaling behaviors within the intact context of the cellular environment, and maintains the 
ability to assess population heterogeneity. Initial attempts to quantify kinase activity involved 
microinjection of 76D into PANC-1 cells and subsequent analysis with CE-LIF. Cells were 
either grown in the presence of serum or starved of serum for 15-24 hrs. In the latter case, 
cells were analyzed after 30 min stimulation with serum (Figure 4.6B). In untreated cells 
(n=11), one cell returned a miniscule amount of 76D phosphorylation (2%), whereas the 
starting peptide, VI-B, underwent phosphorylation ranging between 0-25% (Figure 4.6C). 
The starting peptide also possessed more favorable phosphorylation rates in stimulated cells 
than 76D. The phosphorylated analogue of 76D was injected to determine if the lack of 
reporter phosphorylation was due to dephosphorylation by intracellular protein 
serine/threonine phosphatases (PSPs). This phenomenon was confirmed by the rapid 
dephosphorylation of the reporter within single PANC-1 cells (Figure 4.7). Seeing as 76D 
possesses more favorable phosphorylation kinetics than VI-B, it stands to reason that with 
PSP inhibition prior to microinjection, 76D dephosphorylation could be slowed to the point 
where Akt activity, in the form of 76D phosphorylation, could be observed. Alternatively, the 
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peptide sequence can be modified to limit its recognition by intracellular phosphatases.29 It is 
of note that under all conditions tested, 76D completely resisted proteolytic degradation in 
single cells, demonstrating that the systematic replacement of proteolysis-prone amino acids 
in a sequence is a viable strategy to generate stable peptides. 
4.5 Conclusions 
 An iterative screening process was employed to stabilize locations susceptible to 
proteolysis in the starting peptide reporter VI-B. Locations at the 7th and 8th amino acid 
locations were targeted for modification based on the proteolysis sites observed in PANC-1 
lysates and single cells. Sequential modification at each of these sites followed by 
characterization of stability in lysates as well as suitability as a Akt substrate was evaluated. 
This strategy was successful in generating a substrate more resistant to proteolysis; however 
the rapid dephosphorylation by phosphatases of 76D in individual cells precluded its use as a 
reporter for Akt activity in individual cells. Additional studies will be required to assess if 
this peptide could potentially be utilized as a phosphatase reporter or if PSPs can be inhibited 
to the degree where Akt activity as measured by peptide phosphorylation can be observed. 
Future studies for all peptides described in this work also includes modifications to render 
reporters cell-permeable as well as performing higher-throughput analysis with capillary 
electrophoresis systems.  
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4.6 Figures and Tables 
 
Figure 4.1 Line Bond Structures of Non-native Amino Acids Incorporated in 
the Synthesis of Library Peptides. A) L-phenylalanine derivatives for replacement of 
amino acids at the 8th amino acid cleavage site B) L-alanine derivatives for replacement at 
the 9th amino acid residue 
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Figure 4.2 Electropherograms of Peptide 59D (A) and 59F (B) 60 min After 
Incubation in a PANC-1 Lysate. The asterisk (*) labeled peak in each 
electropherogram represents the peak comigrating with intact, full length peptide. The 
numbered peaks correspond to fluorescent fragments generated by proteolysis.  
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Figure 4.3 Electropherograms of Peptide VI-B (A), 76D (B), 59A (C), 59C 
(D) 60 min After Incubation in a PANC-1 Lysate. The asterisk (*) labeled peak 
represents the peak comigrating with intact, full length peptide. The numbered peaks 
correspond to fluorescent fragments generated by proteolysis.  
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Figure 4.4 Characterization of Peptide Library.  A) In-vitro phosphorylation of 
peptide library by Aktα in the presence of ATP. Phosphorylation (%) was measured as a ratio 
of peak areas between phosphorylated and total reporter in CE electropherograms. B) 
Degradation of peptide library in PANC-1 cytosolic lysates. Intact peptide (%) was measured 
as a ratio of integrated peak areas between intact peptide and fragment peaks in CE 
electropherograms. 
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Figure 4.5 Structure of Myristoylated FAMDA-76D Peptide (Myr76D).  
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Figure 4.6 Microinjection of Peptides Into PANC-1 Cells. A) Standards of 76D, 
phosphorylated 76D (p76D) and all possible fluorescent fragments. F1 corresponds to the 
one-amino acid fragment, and each subsequent number corresponds to a fragment with one 
additional residue at the C terminus B) Electropherogram of PANC-1 cell 2.5 min after 
microinjection with fully intact parent peptide 76D. C) Summary of reporter phosphorylation 
in cells microinjected with 76D and VI-B, and cells with serum stimulation (SS). The bars 
represent the median for each measurement.  
A) B) 
C) 
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Figure 4.7 Dephosphorylation of p76D in PANC-1 Cells. Phosphorylated 76D was 
microinjected into single PANC-1 cells. Dephosphorylation observed at (A) 5 min or B) 2.5 
min timepoints after injection. C) Summary of dephosphorylation 2.5 min after incubation in 
PANC-1 cells, where each data point represents a single PANC-1 cell.  
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
A) B) C) 
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Table 4.1 Properties of the Modified Peptides Derived From Starting Peptide 
VI-B. 
* Indicates starting peptide. Modified residues from VI-B are shown in bold. ND= Not 
determined. Non-native amino acid abbreviations: MeAib : α-(methylamino)isobutyric acid; 
Aib: α-aminoisobutryic acid; BnAla: Benzylalanine; MePhe: N-methyphenylalanine; MeAla: 
N-methylalanine D-Phe: D-Phenylalanine 
 
 
 
 
 
 
 
 
 
 
 
Peptide        Peptide Sequence t50%P (min)  t1/2 (min) 
VI-B* 6FAM-GRP-MeArg-AFTF-MeAla 57 ± 6.8  19 ± 12.1 
76D 6FAM-GRP-MeArg-AFTF-Aib-NH2 40 ± 10.3  352 ± 5.2 
59A 6FAM-GRP-MeArg-AFTF-MeAib-NH2 256 ±7.2  48 ± 13.8 
59C 6FAM-GRP-MeArg-AFTF-BnAla-NH2 167 ± 7.8  20 ± 12.2 
59D 6FAM-GRP-MeArg-AFT-MePhe-MeAla-NH2 ND  43± 7.8 
59F 6FAM-GRP-MeArg-AFT-D-Phe-MeAla-NH2 126 ± 5.7  142 ± 8.4 
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Chapter 5: Pronase E-Based Generation of Fluorescent Peptide Fragments: Tracking 
Intracellular Peptide Fate in Single Cells 
5.1 Overview 
The ability to track intracellular peptide proteolysis at the single cell level is of 
growing interest, particularly as short peptide sequences continue to play important roles as 
biosensors, therapeutics, and endogenous participants in antigen processing and intracellular 
signaling. We describe a rapid and inexpensive methodology to generate fluorescent peptide 
fragments from a parent sequence with diverse chemical properties, including aliphatic, 
nonpolar, basic, acidic, and non-native amino acids. Four peptide sequences with existing 
biochemical applications were fragmented using incubation with Pronase E and/or formic 
acid and in each case a complete set of fluorescent fragments was generated for use as 
proteolysis standards in chemical cytometry. Fragment formation and identity was monitored 
with capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) and matrix 
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-MS) to 
confirm the presence of all sequences and yield fragmentation profiles across Pronase E 
concentrations which can readily be used by others. As a pilot study, Pronase E-generated 
standards from an Abl kinase sensor and an ovalbumin antigenic peptide were then employed 
to identify proteolysis products arising from the metabolism of these sequences in single 
cells. The Abl kinase sensor fragmented at 4.2±4.8 zmol µM-1 s-1 and the majority of cells 
possessed similar fragment identities. In contrast, an ovalbumin epitope peptide was 
degraded at 8.9±0.1 zmol µM-1 s-1 but with differential fragment formation between 
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individual cells. Overall, Pronase E-generated peptide standards were a rapid and efficient 
method to identify proteolysis products from cells. 
5.2 Introduction 
Intracellular proteolytic processing of short peptides is an important biological 
phenomenon, with demonstrated functions in antigen presentation,1 pheromone secretion,2 
gene regulation3 and modulation of signal transduction.4 Proteins and peptides are 
metabolized by complex multi-protein systems such as the proteasome, producing 
oligopeptides subsequently transported in the cytoplasm, secretory granules, or nucleus.5,6 
These short sequences can then continue on to one of many fates, for example, reduction to 
their component amino acids for use as synthetic building blocks, aggregation into disease-
inducing amyloid plaques7, or transportation to the extracellular membrane to act as antigens. 
Additionally, exogenous loading of peptidic sequences into cells has been used to study 
peptide processing8 and intracellular signaling9-12 as well as to deliver drugs and to enhance 
imaging contrast.13 The ability to assess cells individually for specific peptidolytic 
phenotypes is also increasingly desirable such as for the development of engineered T-cell 
therapies or the assay of peptidase heterogeneity for targeted tumor therapeutics. These 
recent advances for the design and delivery of peptide-based therapeutics further fuel the 
growing interest in tracking intracellular peptide stability and fate, particularly at the single-
cell level. Thus tools to enhance the ability to directly monitor peptide reactions within cells 
will have tremendous value in a wide range of areas from sensor development to therapeutics 
and basic physiology. 
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Regardless if sequences are designed to undergo systematic degradation as sensors of 
protease activity, are delivered as a vaccine,14 or used for other purposes, the ability to study 
peptide fragmentation patterns is critical to tracking peptide fate. Measurements of 
intracellular peptide metabolism particularly that incorporate a separation step such as 
chemical cytometry also require a set of fragment standards to unambiguously detect peptide 
fragments.15,16 Facile generation of a full fragment set would enable rigorous characterization 
of the intracellular fate of peptides used as reporters for kinases, phosphatases and other 
enzymes in chemical cytometry as well as applications in mass spectrometry-based 
proteomics and peptide sequencing. Rapid generation of peptide fragments may also 
accelerate the determination of biologically active sequences from larger peptides or proteins, 
such as in the delineation of specific peptide binding motifs for the prediction of T-cell 
epitopes. Currently, this process involves screening all potentially active sequences from a 
parent peptide, requiring the laborious synthesis of all fragments.17  
Methods to generate fragments from a peptide sequence center around three main 
approaches: solid phase peptide synthesis (SPPS), chemical fragmentation, and enzymatic 
digestions. While SPPS is unparalleled at guaranteeing the presence of all desired sequences, 
the synthesis of fragment mixtures from complex cyclized, cross-linked or stapled peptides 
may be highly difficult and can require lengthy chromatographic purification.18 Chemical 
cleavage of peptides has been performed with a variety of reagents such as cyanogen 
bromide, 3-Bromo-3-methyl-2-(2-nitrophenylthio)-3H-indole, formic acid and 
hydroxylamine, which clip C-terminally of methionine, tryptophan, aspartic acid and 
asparagine, respectively.19 However, the nature of chemoselective fragmentation in 
combination with the relatively low abundance of the specified amino acid loci often result in 
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the generation of long peptides. Thus, for the generation of all sequences from a peptide, 
concatenated cleavage steps with multiple reagents may be required and do not guarantee the 
presence of all fragments.  
A popular route to generating peptide fragment ladders is directed enzymatic 
cleavage, a technique borrowed from bottom-up mass spectrometry-based proteomics in 
which proteins are digested with trypsin or chymotrypsin to generate short peptide 
sequences.20 However, these two enzymes have well-defined specificity and only yield 
peptide fragments by hydrolysis at five of the twenty amino acids. In cases where nonspecific 
peptide cleavage is desired, proteases such as Pepsin A and Proteinase K which cleave 
peptides with limited substrate specificity are often employed, although sequence coverage 
with these two enzymes is not 100%.21 Pronase E from the extracellular fluid of 
Streptomyces gresius is a commercially available, broad-specificity mixture of at least ten 
enzymatic components, including five serine-type proteases, two Zn2+ -endopeptidases, two 
Zn2+ -leucine aminopeptidases and a Zn2+ carboxypeptidase.22,23 The reported ability of 
Pronase E to hydrolyze peptide bonds internal to a sequence as well as sequentially remove 
amino acids from both the N and C terminus make this enzyme mixture an attractive 
alternative to enzymatic digestion with trypsin or chymotrypsin, whose regulated activity 
would deliver only specific fragments.24  
  It was hypothesized that the broad range of proteolytic activities afforded by Pronase 
E would affect cleavage at each peptide bond, resulting in a standard mixture of all possible 
fluorescent fragments of a full-length peptide. Herein, we demonstrate the utility of Pronase 
E as a nonspecific, rapid, and inexpensive method to generate fluorescent peptide fragment 
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ladders. We also introduce the use of secondary formic acid digestion as a post-enzymatic 
step to promote the formation of acidic fragments. Fragment formation and identity were 
synergistically monitored with CE-LIF and MALDI-MS in parallel. Finally, peptide fragment 
standards generated by Pronase E were then applied to identification of degradation products 
from peptide-based probes in single cell assays. Peptide ladders generated by Pronase E 
should have wide applicability in the identification of degradation products in single cell 
assays, for peptide sequencing purposes, and for the generation of biologically active 
sequences when identifying immunogenic epitopes.  
5.3 Experimental Section 
5.3.1 Chemicals 
  Aside from the following reagents, chemicals were purchased from Sigma Aldrich or 
Fisher Scientific. For cell culture, Dulbucco’s Modified Eagle’s Medium (DMEM) was 
acquired from Cellgro; Penicillin/streptomycin was obtained from Gibco, and fetal bovine 
serum (FBS) was purchased from Atlanta Biologicals.  
5.3.2 Peptide Synthesis 
The full length peptides I-III (Figure 5.1A) were synthesized using standard SPPS 
methodology on TGR resin, while peptide acid fragments were synthesized on 2-
chlorotritylchloride resin, both using an automated peptide synthesizer (PS3, Protein 
Technologies, Tuscon, AZ). Each was fluorescently labeled at the N-terminus with either 5 or 
6FAM. Fmoc-Asp(OMpe)-OH was used in the synthesis of Peptide III to prevent 
racemization through aspartimide formation. Synthesis of Peptide IV was performed at the 
High-Throughput Peptide Synthesis and Arrays (HTPSA) Core Facility at the University of 
North Carolina at Chapel Hill. 
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5.3.3 Cell Culture 
PANC-1 cells were obtained from the American Type Culture Collection and 
maintained in a humidified atmosphere of 37°C in 5% CO2. Cells were cultured in DMEM 
supplemented with 10% FBS, penicillin (100 units/mL) and streptomycin (100 µg/mL) and 
were passaged at 60-80% confluence with 0.25% trypsin solution. Cells were plated for 
single-cell analysis the day prior to analysis by adding a dilute cell solution to 400 microliters 
of DMEM media in cell chambers.  
5.3.4 Pronase E Peptide Digestions 
Pronase E from Streptomycies gresius was prepared in phosphate buffered saline 
(PBS; 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM HCl, 1.75 mM KH2PO4, pH 7.4) to 2 
mg/mL. Assessment of peptide degradation was performed in triplicate by combining peptide 
(10 µM) with various concentrations of Pronase E (0.001 µg/mL-1000 µg/mL) and 
incubating at 37°C. Aliquots were removed at time points and inactivated at 90°C for 4 min. 
Negative controls without peptide were concurrently sampled and heat-inactivated. Samples 
were diluted 100X in electrophoretic buffer prior to separation and detection with CE-LIF. 
5.3.5 Supplemental Formic Acid Assisted Digestion 
Additional fragments of Peptide III were generated by incubating partially digested 
samples from Pronase E assays in 1-5% formic acid solution at 37°C. Aliquots were 
neutralized with an equal volume of 200 mM NaOH to bring the pH to 6.5-7.5. 
5.3.6 Capillary Electrophoresis 
For separations not involving single cells, CE-LIF (488 nm) was performed using a 
Proteome-Lab PA 800 (Beckman Coulter, Fullerton, CA) equipped with 30 cm fused silica 
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capillaries of 30 or 50 µM inner diameter, 360 µM outer diameter (Polymicro Technologies, 
Phoenix, AZ). Electrophoretic buffers for Peptides I, II, III, and IV were 100 mM tris, 100 
mM tricine, pH 8.1; 140 mM borate, 70 mM sodium dodecyl sulfate (SDS), pH 9.5; 300 mM 
borate, pH 7.5; and 100 mM tris, 100 mM tricine, 5 mM sodium cholate, pH 8.1, 
respectively. Electropherograms were integrated using customized software20 constructed 
using MATLAB (Natick, MA). 
5.3.7 MALDI-MS Analysis 
 MALDI-MS analyses were performed in high-resolution reflectron mode with an AB 
SCIEX 4800 Plus instrument equipped with a 337 nm laser. Peptide standards and assay 
samples were diluted in deionized water to 3 µM. Samples were prepared by spotting a 500 
nL sample volume onto a 364-spot MALDI sample plate immediately followed by 500 nL of 
saturated α-cyano-4-hydroxycinnamic acid matrix solution. Spots were air-dried under 
laminar flow. The laser intensity was set to 4200 mW and 50 shots were averaged for the 
peptide spectra. 
5.3.8 Single Cell Capillary Electrophoresis 
 Custom glass chambers for housing cells were placed on the stage of a customized 
single-cell CE system with LIF detection (488 nm).25 Cells were microinjected with 100 μM 
peptide (I or IV) using a Transjector 5246 microinjection system (Eppendorf AG, Hamburg, 
Germany). Cells were maintained at 37°C with a constant flow of warmed extracellular 
buffer (ECB; 10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, pH 
7.4) throughout incubation and analysis. At 2 min post microinjection, the cell was lysed 
with a focused Nd:YAG laser pulse as previously described26 and the contents injected into 
the capillary by applying a negative potential to the capillary outlet reservoir (5 s at 79 
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V/cm). For separations of single cells microinjected with Peptides I or IV, electrophoresis 
was performed in respective buffers at -171 and -263 V/cm, respectively. 
5.4 Results and Discussion 
5.4.1 Experimental Overview 
The goal of this work was to develop a simple strategy to generate fluorescent peptide 
fragments regardless of their sequence or structure. To that end, a small collection of 
chemically diverse peptides with existing biochemical applications was selected (Figure 
5.1A), and the efficacy of Pronase E in generating fragments as a function of substrate 
chemistry and enzyme concentration was examined. Each peptide under investigation was 
incubated with Pronase E at varying concentrations for up to 60 min (Figure 5.1B,C). 
Samples were then divided into two equivalent fractions and subjected to parallel analysis by 
CE-LIF and MALDI-MS in order to determine how many fluorescent fragments were 
generated (Figure 5.1D). The number of fragments formed and the rate of peptide 
degradation was determined from the number and area of peaks appearing in 
electropherograms (see Figure 5.1A for fragment nomenclature for Peptides I-III, Table 5.1 
for Peptide IV). MALDI-MS identified which fragments formed under the different 
conditions. To validate the identity of fragments in electropherograms, all fluorescent 
fragments of Peptides I-III were synthesized using SPPS to identify unique electrophoretic 
and mass footprints. We then applied the assay to the formation and identification of 
fragments from Peptide IV, an ovalbumin epitope sequence without synthesized standards. 
Pronase E-generated standards were then employed to identify peptides formed due to 
protease activity in single cells. 
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5.4.2 Identification of fragments formed in Pronase E assays 
For peptides I-III, standards of all possible fluorescent peptide fragments were 
synthesized, purified, and characterized by CE-LIF. Separation methods were developed for 
each peptide under which all N-terminal fragments were resolved from the parent peptide 
and from all other species. This allowed facile identification of Pronase E cleavage sites for 
each peptide. Full length peptides were incubated with Pronase E, and after stopping the 
reaction each of the possible fluorescent peptide standards was sequentially added into the 
reaction mixture to identify peptide fragments by CE-LIF. Each peak present in the CE 
analysis of the assay sample was attributable to a standard fragment, permitting unambiguous 
identification of each fragment formed. Intact full length peptide was identified by adding 
standard peptide to the heat-inactivated aliquots. Peaks appearing at migration times differing 
from the full length peptide were identified as fragments by the addition of synthesized 
fragment standards and/or by confirming the presence of fragment masses by MALDI-MS. 
The percentage of intact parent peptide was calculated by the ratio of the peak area of intact 
peptide to that of all peaks in the electropherogram. 
To identify fragments of Peptide IV, a combination of CE-LIF and MALDI-MS were 
utilized. As proof of principle, fragments were identified without the use of synthesized 
standards. Because it is labeled on an internal lysine sidechain, fluorescent fragments of 
Peptide IV may be formed by removal of amino acids from both the N and C terminus; 
therefore fragment nomenclature was based on mass (Table 5.1). Samples resulting from 
digestions at various Pronase E concentrations were subjected to MALDI–MS until a 
condition was identified that generated all possible fragments. When the mass for at least one 
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member of an identical mass pair for peptide IV was identified by MALDI-MS, 50% of that 
detected was arbitrarily assigned to each fragment in the pair. 
5.4.3 Enzymatic Generation of Peptide I Standards 
 Peptide I (5FAM-GGAYAAPFKKKA-NH2), a sequence employed as an Abl kinase 
sensor, contains primarily hydrophobic and basic residues and was well matched to the 
reported specificity of Pronase E.22,23 All fragments of Peptide I were readily separated in an 
optimized10 buffer system (Figure 5.2A) and efficiently detected by MALDI-MS (Figure 
5.2B). Due to moderate salt levels in the sample matrix, Peptides I-k, I-g, I-f, and I-e often 
ionized as sodium or potassium adducts, which are denoted in mass spectra by asterisks (*). 
After verifying that all fragments possessed unique electrophoretic and mass footprints, 
Peptide I was incubated with Pronase E and the assays sampled over time by CE-LIF to 
assess the formation of fluorescent fragments. Complete degradation into all representative 
fragments was observed after incubation with 0.02 µg/mL enzyme for 15 min, represented by 
the appearance of 11 new peaks in electropherograms (Figure 5.2C) and the identification of 
each fragment mass by MALDI-MS (Figure 5.2D). Fragments I-j (23±4.2%) and I-l 
(30±5.6%), resulting from cleavage at Ala-Tyr and Gly-Gly bonds, respectively, were among 
the predominant fragments formed, although all 11 were detected by both CE-LIF and 
MALDI-MS. Taken with data from incubation of Peptide I with more concentrated solutions 
of Pronase E (Figure 5.3A), these results indicated that the enzyme mixture first hydrolyzes 
multiple peptide bonds within a sequence before reducing the peptide to the shortest peptide 
fragments. Overall, Pronase E was capable of generating all fluorescent fragments of Peptide 
I in as short as 15 min, which, at minimum, is 50 fold faster than by SPPS.  
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5.4.4 Enzymatic Generation of Fragments for Peptide II 
 After verifying that Pronase E could be used to generate fragments of a peptide 
containing residues similar to its reported preference, a longer and more charge diverse 
sequence was evaluated. Peptide II (6FAM-RAHEEIYHFFFAKKK-NH2) is a substrate of 
epidermal growth factor receptor (EGFR) tyrosine kinase and has found widespread utility 
for in vitro enzymatic characterization of EGFR.27,28Containing aromatic, aliphatic, acidic, 
and basic residues, Peptide II represents a chemically-diverse testing ground for the 
formation of fragments by this enzyme mixture. Peptide II was incubated with various 
concentrations of Pronase E, and aliquots were removed over time and heat inactivated. 
Samples were separated with CE-LIF to detect the formation of fluorescent fragments. As 
with Peptide I, preparations of Pronase E below 0.001 µg/mL were insufficient to produce 
any detectable proteolysis within 60 min. However, after increasing the Pronase E 
concentration to 0.01 µg/mL for 15 min, only 13.5±4.5% of the full length peptide remained, 
and 9 of 15 fragments were formed and separated by CE-LIF (Figure 5.3B). The primary 
products were II-d (22.3±3.4%) and II-g (15.8±2.6%), resulting from cleavage at Ala-Arg 
and Phe-Phe bonds, respectively. After treatment with up to 0.01 µg/mL Pronase E, the 
shortest fluorescent fragment detected was 7 amino acids (II-i; 11.6±2.1%), which, taken 
with results from Peptide I, suggests that at these and lower concentrations of lower E 
possesses greater activity towards charged and hydrophobic residues. No fragments resulting 
from cleavage at sites upstream of position 7 (II-i) were detected, despite reports of an acidic 
amino acid-specific endopeptidase purified from Pronase E which preferentially cleaves at 
such sites. 
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 0.1 µg/mL Pronase E was required to form all 15 fragments within 15 min (Figure 
5.3B, Figure 5.4B). Although fragments II-l and II-m formed less than 2% of the total 
fragments detected by CE-LIF, these were readily identified with CE-LIF and also with 
MALDI-MS (Figure 5.5). With further increased enzyme concentration (5 µg/mL), the 
majority of fragments furnished from digestion were low mass short fragments, namely II-n 
and II-o. While a moderate concentration of Pronase E was sufficient to generate all 
fragments, it should be noted that pooling samples from differing concentrations which 
contain overlapping sequence coverage is a method in which the desired fragments can be 
obtained. 
5.4.5 Pronase E digestion of degradation resistant Peptide III 
In order to assess limitations of Pronase E to generate all fluorescent fragments of a 
peptide, a degradation resistant sequence was identified and synthesized, along with its 
corresponding fluorescent fragments. Peptide III (6FAM-LEDDYEDDNle-NH2, where Nle 
is Norleucine) was adapted from a substrate of protein tyrosine phosphatases (PTPs).9 In 
single cells, the median half-life of the peptide was 35 min; 70-fold longer than that of 
Peptide I.11,29 Though truncated from its original 13 amino acid sequence, Peptide III 
possesses 80% of the glutamic and aspartic acid residues to which its degradation resistance 
was attributed. This peptide also contains a non-native amino acid, which confers resistance 
to degradation, presumably due to the limited ability of peptidases to recognize non-coding 
amino acids.30,31 
Peptide III was resistant to enzymatic degradation 60 min after incubation with 50 
µg/mL Pronase E, a 500-fold more concentrated solution than that required to generate all 
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fluorescent fragments of Peptide II in 15 min. However, by incubating the peptide with 500 
µg/mL Pronase E for 15 min all fluorescent fragments were generated and detected with CE-
LIF (Figure 5.6A). As expected, the majority of fragments formed during digestion were the 
result of cleavage between native amino acids. The three fragments forming in the smallest 
percentages were all generated by cleavage between two acidic residues (III-c, e, g), which 
falls in agreement with reports of the resistance of peptide bonds between anionic residues to 
hydrolysis.29 Due to the highly sensitive nature of CE-LIF, several fragments formed in small 
quantities detectable by CE but were not identified through MALDI-MS analysis (Figure 
5.6B). These included III-b, c and e, all fragments resulting from cleavage involving acidic or 
non-native amino acids, which were identified with fragment standards. Increasing the 
Pronase E concentration to 1000 µg/mL had the effect of generating a higher fraction of short 
(<5 residues) peptides and fragment III-b due to cleavage of Nle (Figure 5.3C), but fragments 
such as III-c, III-e and III-g were never formed in amounts greater than 3% of the total 
fragments detected in electropherograms, and were rarely detected with MALDI-MS.  
5.4.6 Formic Acid-Assisted Degradation of Peptide III 
We hypothesized that the acidic nature of Peptide III contributed to the limited 
formation of several fragments and our resultant inability to detect some fragments with 
MALDI-MS. Thus, we sought a method which could be used in combination with Pronase E 
to generate fragments in a more equivalent fashion. Given that conditions for the selective 
cleavage of peptides and proteins at the carboxyl side of acidic residues such as aspartic acid 
using formic acid had been reported,32 we selected formic acid for digestions. Formic acid 
treatment alone was insufficient to generate all fragments (Figure 5.7). However, if Peptide 
III was first partially hydrolyzed with 500 µg/mL Pronase E for 15 min, heat-inactivated, and 
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then exposed to 2% formic acid for 15 min at 37°C, all 8 fragments were detected along with 
native peptide. The fraction of peptides produced due to cleavage at the C-terminal end of 
aspartic acid residues each improved to a minimum composition of 6%, and was easily 
detected with CE-LIF (Figure 5.6C). The use of formic acid also resulted in improved 
sensitivity and better representation of true peptide stoichiometries in MALDI-MS spectra 
(Figure 5.6D), presumably due to improved ionization garnered after protonation by formic 
acid.33 Overall it was found that the combination of enzymatic and chemical peptide 
hydrolysis produced a simple, rapid, and novel method to nonspecifically generate fragments 
of an acidic, degradation-resistant peptide.  
5.4.7 Degradation of an immunogenic peptide with an internal fluorophore 
 Intracellular peptide metabolism gives rise to many compounds of biological 
importance, including epitopes recognized by cytotoxic T-cells (CTL). Use of these antigens 
as immunotherapy is a promising new treatment for patients with advanced stage oncological 
malignancies, but antigen immunotherapy is limited by the paucity of suitable peptide 
antigens that are recognized by CTLs,34 necessitating laborious epitope mapping screens in 
which full length peptides and all possible truncated active sequences must be synthesized. 
Thus, a mixture of all possible fragments from a potential epitope-containing peptide or 
protein could be useful, especially since it has been shown that pooling of peptide fragments 
does not cause masking of the active sequences in high-throughput screens.35 Peptide IV 
(SIINFE(K-5FAM)L-OH) is the 256-264 residue class I (Kb)-restricted peptide of 
ovalbumin, a frequently modeled epitope in the context of the major histocompatibility 
complex (MHC) Class I allotype. It has been demonstrated that the peptide can be used to 
elicit strong CD8+ cytolytic T cell responses.36 Although presentation of Peptide IV requires 
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no further proteolytic processing, this sequence acted as proof of principle for the enzymatic 
generation of all possible fluorescent fragments of an active epitope with Pronase E. 
 To establish whether all fragments of a peptide with an internal fluorophore could be 
generated without the use of synthesized standards, Peptide IV was incubated with varying 
amounts of Pronase E until the maximum number of fluorescent fragments (nomenclature; 
Table 5.1) were identified with MALDI-MS (Figure 5.8). Compared to Peptides I-III, an 
intermediate concentration of Pronase E (5 µg/mL) was required to generate all fluorescent 
fragments of this sequence (Figure 5.3D). Three pairs (IV-d/e, IV-f/g, and IV-h/i) of Peptide 
IV fragments possessed similar or identical masses (Table 5.1) and could not be 
unambiguously identified by MALDI-MS alone, making identification of these fragments a 
unique challenge. One species, fragment IV-n, could not be identified by MALDI-MS, 
potentially due to poor ionization under the conditions tested. To ensure that all fluorescent 
fragments were indeed formed, the same sample was subjected to separation with CE-LIF. 15 
unique peaks were identified, each presumably representing a fragment. Since sequence-
specific identities could not be assigned to peaks appearing in electropherograms, fragments 
of Peptide IV detected by CE-LIF were labeled with roman numerals according to migration 
time (Figure 5.9D). While the sequence of each fragment cannot be determined by migration 
time alone, the combination of MALDI-MS and CE-LIF data indicates that each fragment is 
present. Based on the MALDI-MS analysis, we can speculate that fragments formed in 
greater quantities, such as IV-a and IV-k, may correspond to species generating a large peak 
area in CE-LIF analysis, such as IV-xiii and IV-ii, respectively. Peptide IV was identified as 
IV-ix based on co-migration with the synthetic full length sequence. Interestingly, the 
contents of the slowest migrating peak in Figure 5.9D and Figure 5.10 co-migrated with the 
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free fluorophore (5FAM) which was not observed in Pronase E assays with Peptides I-III, 
which are fluorescently labeled on the N-terminus rather than an internal residue. Overall, 
Pronase E was a rapid and simple method to generate fluorescent fragments regardless of the 
fluorophore placement. Thus, this technique finds applications in comprehensive fragment 
profile generation with the exact sequence-specific peptides being unknown. However, in 
such cases where comprehensive fragment profiles are generated without the use of 
synthesized standards, a secondary method of peptide sequence generation or a combination 
of separation and mass spectrometry may be required if identification of sequence-specific 
fragments is desired. 
5.4.8 Tracking proteolysis of peptides in single cells 
 Single-cell CE-LIF permits highly sensitive (10-20 mole)9,25 enzyme activity 
measurements within individual cells. However in order to identify species arising from 
reporter or peptide degradation, it is necessary to generate a set of peptide standards which 
represent all possible degradation products for use as migration standards. This is especially 
true when the degradation products of peptides within individual cells are unknown and may 
co-migrate with other peptide modifications such as phosphorylation or acetylation. 
Although mass spectrometric methods have the capability to directly assign species 
identities, the combination of high-salt physiological buffers, limited sensitivity, variable 
analyte ionization, and small sample volumes have proven generally incompatible with mass 
spectrometry to directly identify products from single cells.15,37-39 To demonstrate the utility 
of a simple and rapid method to generate all fluorescent fragments in tracking single-cell 
peptide metabolism, the intracellular fate of peptides was tracked in single-cells by CE-LIF.  
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Peptide I (38±9 amol, n=4 cells), or IV (46±15 amol, n=7 cells) was microinjected 
into individual PANC-1 cells, a pancreatic adenocarcinoma cell line. This cell line was 
chosen based our observations that PANC-1 cells possess robust proteolytic activity and 
would likely generate fragments of the selected peptides.25 Peptide was incubated for 2 min 
before cells were lysed with a pulse from an Nd:YAG laser and the contents loaded into a 
capillary directly above the cell. Intracellular metabolism of the peptide was identified using 
standard fragment mixtures obtained from incubation with Pronase E. With the exception of 
a peak detected due to cell fluorescence (Figure 5.9D), each fragment formed in the cell co-
migrated with a standard fragment suggesting that all cell-derived peaks were fragments 
formed by cleavage at peptide bonds and were not due to other metabolic processes such as 
phosphorylation or acetylation, which would likely shift the migration times observed in CE-
LIF. 
During a 2-min incubation, Peptide I, an Abl kinase sensor, underwent proteolysis 
within the cytosol of all intact cells analyzed, and all fragments were identified through the 
use of Pronase E-generated standards. The five-residue fragment I-h, a result of cleavage 
between the Ala-Ala residues (Figure 5.9A), was preferentially formed in all cases. Similar 
peptide cleavage sites were observed among the cells analyzed, with between 5-7 fragments 
formed within the 2 min incubation period, and the identities of fragments formed between 
cells varied only slightly (Figure 5.9E and 5.11). No fragments shorter than 3 amino acids 
were observed. The average rate of degradation of Peptide I within cells was 4.2±4.8 zmol 
µM-1 s-1, and resulted in 24-78% intact Peptide I after 2 min. While one of the four cells 
tested did not exhibit significant amounts of peptide fragment generation, the peptides 
generated possessed similar profiles between cells (Figure 5.11). The variability in absolute 
159 
 
fragmentation rate observed in these studies combined with previous work displaying the 
rapid fragmentation of this peptide sensor in single cells10 indicates that in numerous cases 
this sequence is quickly degraded and requires fragmentation monitoring within the 
intracellular environment, even in cases where peptide phosphorylation is the desired 
readout.  
Peptide IV was also rapidly metabolized in cells, with an average of 8.8±5.3% intact 
remaining after 2 min (Figure 5.9B). The average rate of proteolysis was 8.9±0.1 zmol µM-1 
s-1. Although Peptide IV requires no additional proteolytic processing for antigen 
presentation, its limited intracellular lifetime suggests rapid peptidase activity towards this 
sequence. This is consistent with advancement of degraded peptides to one of multiple fates, 
including binding to MHC class I molecules to become immunologically relevant or acting 
as substrates for various cytosolic peptidases which hydrolyze peptides into their component 
amino acids.6 The 7 individual cells produced between 3-11 unique fluorescent peptide 
sequences, with no two cells possessing the same profile of fragments (Figure 5.9F and 5.12). 
The constant incubation time combined with the negligible correlation between the number 
of fragments generated in individual cells and amount of Peptide IV delivered by 
microinjection (R2 = 0.15, Figure 5.13) indicates that the cleavage site heterogeneity was not 
a function of the loading technique or duration. While additional single cell analyses will be 
required to provide further evidence of any subpopulations of cells with differential 
proteolysis phenotypes, these pilot studies show the ease and feasibility of tracking 
intracellular peptide fate with standards generated by Pronase E. The variation in fragments 
formed in single cells as identified by Pronase E standards may provide useful biological 
information even without certainty of peak assignments, particularly in cases where specific 
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peaks act as bioindicators. Variations in fragment number or degradation rate can be a simple 
indicator of the activation or inhibition of enzymes or particular pathways upon drug 
treatment, sample handling practices, or upregulation as a result of a disease state.40,41  
5.5 Conclusions 
Rapid digestion of peptide sequences with Pronase E and synergistic CE-LIF and 
MALDI-MS detection of fluorescent fragments was validated in vitro and implemented in 
the identification of fragments from single cells. A small but chemically diverse group of 
peptide sequences underwent proteolysis with Pronase E, and conditions for the hydrolysis of 
basic, polar, and nonpolar amino acids within a sequence were demonstrated. Synthesized 
fragments were employed to verify the identities of sequences in initial studies (Peptides I-
III), and then all fragments from Peptide IV were generated and identified from assay 
mixtures alone. It was shown that limited hydrolytic capabilities of Pronase E towards acidic 
or non-native amino acids could be overcome by supplementing enzymatic degradation with 
formic acid-induced peptide cleavage. The formation of peptide fragments was tracked in 
single PANC-1 cells, and the simultaneous identification of degradation products as well as 
the rate of their formation was achieved with a combination of Pronase E-generated fragment 
standards and chemical cytometry. In cells incubated with Peptide IV, there was substantial 
variation in the identity of fragments formed between cells. This heterogeneity reflects the 
value of single cell analysis, as the unique fragment profiles formed in each cell would not be 
visible in population averages.  
This approach for the generation of peptide fragments has several advantages over 
existing methodologies, primarily in its simplicity and flexibility. The relatively nonspecific 
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nature of Pronase E is well suited to the generation of fragments from a wide range of 
peptides, and by varying the concentration of enzyme mixture, even degradation resistant 
sequences can be fragmented. Based on our success with post-enzymatic chemical peptide 
cleavage, it stands to reason that directed chemical cleavage with other reagents in cases 
where Pronase E is insufficient is possible, and will be the focus of further studies. Overall, 
the use of Pronase E to rapidly generate fragments should see wide applicability in peptide 
sequencing, rapid generation of biologically active peptides from larger proteins, and in 
generation of fragment standards for chemical cytometry.  
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5.6 Figures and Tables 
 
Figure 5.1 Schematic of a Pronase E Peptide Degradation Assay. A) 
Synthesized full length peptides for individual degradation by Pronase E. Uppercase letters 
represent single letter amino acid abbreviations, Nle is Norleucine, and NH2 or OH represent 
amidated or carboxylated C-termini, respectively. Lowercase letters indicate cleavage 
locations that form the specified fluorescent peptide fragments. Fragment nomenclature for 
Peptide IV can be found in Table 5.1. B) Each peptide was incubated with active Pronase E. 
Colored circles represent the different amino acids present in each sequence, and stars 
represent fluorescein (FAM). C) The resulting mixture containing fluorescent fragments. D) 
Results of parallel CE-LIF and MALDI- MS analysis identifying fluorescent fragments.  
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Figure 5.2 Separation and Detection of Peptide I Fragments. A) CE-LIF 
separation of peptide fragments prepared by SPPS. B) Positive-ion MALDI-MS spectra of 
synthesized Peptide I fragments. C) CE-LIF separation of fragments generated by incubation 
of Peptide I with 0.02 µg/mL Pronase E for 15 minutes. D) Positive-ion MALDI-MS spectra 
of Pronase E assay sample separated in (C).  
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Figure 5.3 Summary of Pronase E Degradation Profiles for Peptide A) I B) 
II C) III D) IV. Each plot represents the fragments formed during 15 minutes incubation 
with the indicated enzyme concentration (µg/mL). The blue layer signifies the Pronase E 
concentration that generated the most complete distribution of fragments. The percentage of 
fragment formation (0-100%) is scaled independently for each fragment. Fragment (I-IV)a in 
each plot indicates the full length peptide sequence. With the exception of Peptide IV 
(Fragment nomenclature in Supplemental Table S1) each subsequent letter represents the 
fragment resulting from removal of one residue from the C-terminus. The variation in 
fragment formation between replicates of each peptide’s optimized Pronase E concentration 
(blue layer) is described in Figure 5.4. 
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Figure 5.4 Fragment Formation Under Optimized Pronase E Conditions for 
Peptide A) I B) II C) III D) IV. The solid bars represent the percentage peptide formed 
in the reaction mixture while the error bars represent the standard deviation (n = 3).  
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Figure 5.5 Positive-ion MALDI-TOF MS Spectra of Peptide II Fragments 
Formed by 0.01 µg/mL Pronase E After 15 min. 
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Figure 5.6 Digestions of Peptide III.  A) Electropherogram of fragments generated 
with 500 µg/mL Pronase E and separated with CE-LIF. B) MALDI-MS spectra 
corresponding to digestion of Peptide III with Pronase E alone C) CE-LIF separation of 
Peptide III fragments generated with 2% formic acid-assisted Pronase E digestion D) 
MALDI-MS spectra of Peptide III fragments generated with 2% formic acid-assisted Pronase 
E digestion. 
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Figure 5.7 Fragmentation of Peptide III After Incubation with 2% Formic 
Acid for 15 min.  
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Figure 5.8 Negative-ion Mode MALDI-MS Spectra of Peptide IV Digested 
With 5.0 µg/mL Pronase E for 15 min.  
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 Figure 
5.9 Identification of Fragments Formed Due to Peptide Metabolism in Single 
Cells Based on Pronase E-Generated Standards. PANC-1 cells were microinjected 
with Peptide I (A,C,E) or Peptide IV (B,D,F). (A,B) Electropherograms of a single PANC-1 
cell 2 min after microinjection. The Pronase E generated standards of Peptide I (C) or IV (D) 
were loaded into the capillary immediately after loading the cell contents. Electrophoresis 
was then initiated by applying a voltage to the capillary, which resulted in concurrent 
separation of fragment standards and cellular contents. Radar plots for Peptide I (E) and 
Peptide IV (F) indicate the fragments formed in individual cells.  
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Figure 5.10 CE-LIF Separation of Peptide IV Fragments Generated with 
Pronase E (5.0 µg/mL) Without the Addition of PANC-1 Cell Contents.  
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Figure 5.11 CE-LIF Separation of Single PANC-1 Cells Microinjected With 
Peptide I for 2 min . Electropherograms from Cells 1-4 can be matched with radar plots in 
Figure 5.8E. 
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Figure 5.12: CE-LIF Separation of Single PANC-1 Cells Microinjected with 
Peptide IV for 2 min. Cell identification numbers can be matched to radar plots in Figure 
5.8F.  
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Figure 5.13 Peptide IV Fragmentation as a Function of the Number of Moles 
of Peptide Loaded into Intact Cells.  
 
 
 
 
 
 
 
175 
 
Table 5.1: Fragment Nomenclature and Masses for Peptide IV 
Name Sequence Mass 
IV-n K(5-FAM)-OH 504.15 
IV-m K(5-FAM)L-OH 617.24 
IV-l EK(5-FAM)-OH 634.18 
IV-k EK(5-FAM)L-OH 747.26 
IV-j FEK(5-FAM)-OH 781.25 
IV-i FEK(5-FAM)L-OH 894.33 
IV-h NFEK(5-FAM)-OH 895.29 
IV-g NFEK(5-FAM)L-OH 1008.38 
IV-f INFEK(5-FAM)-OH 1008.38 
IV-e INFEK(5-FAM)L-OH 1121.46 
IV-d IINFEK(5-FAM)-OH 1121.46 
IV-c SIINFEK(5-FAM)-OH 1207.51 
IV-b IINFEK(5-FAM)L-OH 1234.54 
IV-a SIINFEK(5-FAM)L-OH 1320.59 
 
Peptide IVa represents the full-length peptide. In Figure 5.9(B,D), Peptide IV fragments are 
named by lowercase roman numerals based on migration time. 
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